



Pharma Solutions Product Overview

Inspiring Medicines for Better Lives

 BASF Pharma Solutions
pharma.basf.com
MarComm-2025-00064

We produce excipients and active ingredients of outstanding quality and performance. Our team of experienced industry specialists supports you in developing effective, reliable formulations – giving you a vital advantage in a highly demanding market.

Equipped with an in-depth understanding of multiple industries, technologies, and applications, we have the skills and resources to make drug manufacturing and drug delivery more efficient, robust, and cost-effective. Whether you want to make your medicine more effective, safer, or just more patient-friendly, BASF has the solution you need.

This brochure presents an overview of our leading-edge products, grouped in the following platforms: Orals, Topicals, Parenterals, Solubilization, Biopharma Ingredients and APIs. Details on functionality are clearly provided for each product – allowing you to quickly and easily find the right answers to your pharmaceutical formulation challenges.





**Delivering
what
matters**

Meet your Virtual Pharma Assistants!

At BASF, we know how important innovation, speed-to-market, and cost-effectiveness are to our pharmaceutical customers and collaboration partners. The Virtual Pharma Assistants bundle BASF's extensive expertise in formulation and regulatory/quality compliance. Whether you are looking for the right formulation or product solution or need compliance documentation, your Virtual Pharma Assistant is there, whenever and wherever you need it.



ZoomLab™

Your virtual formulation assistant

Save time and money.
Instantly predict your next formulation now!



RegXcellence®

Your virtual quality & regulatory assistant

Simplify the compliance process.
Instantly access documentation & more!



MyProductWorld

Your virtual product assistant

Find the optimal excipient or API solution for your next formulation challenge!



<https://info-mypharma.basf.com/>

| | | |
|---|--|--------------------|
|  | Orals | 06 |
| | Core formulation | |
| | Coating formulation | |
|  | Topicals | 14 |
| | Creams, foams, ointments and gels | |
| | Topical polymeric films | |
| | Transdermal patches | |
| | Suppositories | |
|  | Parenterals | 22 |
|  | Solubilization | 24 |
| | Solid dispersions | |
| | Solutions | |
| | Emulsions | |
| | Suspensions | |
| | Softgel and capsule fills | |
|  | Biopharma Ingredients | 34 |
|  | APIs | 38 |
|  | Pharma Solutions Product Overview by Chemistry | 42 |



Orals

Our broad portfolio offers a range of functionalities for oral dosage forms designed to enhance their effectiveness and meet diverse needs in the market. Our high-quality products enable you to formulate pharmaceuticals with the exact release properties you desire. This ensures the right results every time – giving you that all-important competitive edge.

We are a trusted industry player with a proven track record, going back to the invention of PVP (marketed under the brand name Kollidon®) in the 1930s. We have continued to expand and enhance our portfolio ever since – with innovative, multifunctional excipients such as for tableting, film-coating, and process enhancement, targeted to achieve the desired drug release profile. These products reflect our dedication to highly effective, reliable, and resource-efficient solutions that help you confidently design the dosage form that you need.





<https://pharma.basf.com/solutions/orals>





Core formulation

| Functionality | Process | | | Dosage form | | | Product | Description | Monograph title*/ Chemical name |
|---------------|--------------------|---|-----------------|----------------------|---|-----|--|---|---|
| | Direct compression | Dry granulation (incl. roller compaction) | Wet granulation | Tablets and capsules | Particles (granules, pellets, and MUPS) | ODT | | | |
| Binders | | | ● | ● | ● | ● | Kollidon® 25/ Kollidon® 30 ^Δ | P The PVP from the originator. Medium molecular weight povidone with PeroXeal® packaging for longer shelf life. | Ph. Eur., USP-NF, JP: Povidone |
| | | | ● | ● | ● | ● | Kollidon® 30 LP | P Our low peroxide povidone 30 grade with an antioxidant to protect sensitive drugs from peroxides. | Ph. Eur., USP-NF, JP: Povidone |
| | ● | ● | ● | ● | ● | | Kollidon® 90 Evo | P Highly effective water soluble binder with low impurity profile. | Ph. Eur., USP-NF, JP: Povidone |
| | | | ● | ● | ● | ● | Kollicoat® IR | Low viscous, soluble, and peroxide-free wet binder with great performance, and especially recommended for peroxide-sensitive drugs.. | Ph. Eur.: Macrogol poly(vinyl alcohol) grafted copolymer; USP-NF: Ethylene glycol and vinyl alcohol graft copolymer; JPE: Polyvinyl alcohol-polyethylene glycol graft copolymer |
| | ● | ● | ● | ● | ● | | Kollidon® VA 64 | Effective binder recommended for direct compression and dry & wet granulations. Excellent solubilizer matrix for ASD. | Ph. Eur., USP-NF: Copovidone; JPE: Copolyvidone |
| | ● | ● | | ● | ● | | Kollidon® VA 64 Fine | Highly efficient dry binder with fine particle size for improved compressibility indicated for dry granulation and direct compression. Extremely recommended for MUPS in tablets. | Ph. Eur., USP-NF: Copovidone; JPE: Copolyvidone |
| | ● | ● | | ● | ● | | Kollidon® CL-M | Dry binder recommended for dry granulation and direct compression with slight disintegration functionality. | Ph. Eur., USP-NF, JP: Crospovidone type B |
| | ● | ● | | ● | ● | ● | Kollidon® CL-SF | P 2 in 1 functionality: efficient dry binder with a disintegrant functionality, recommended for direct compression and dry granulation. | Ph. Eur., USP-NF, JP: Crospovidone type B |
| Disintegrants | ● | ● | ● | ● | ● | | Kollidon® CL | P Fast and pH-independent disintegrant, presenting good tableting and solubilizing properties. Its working principle is swelling without gelling, allowing higher concentrations (5 to 15%) without negatively impacting the disintegration. | Ph. Eur., USP-NF, JP: Crospovidone type A |
| | ● | ● | ● | ● | ● | | Kollidon® CL-F | P Fine crospovidone providing a balance of fast disintegration and optimal tableting properties, recommended for medium to large tablets. | Ph. Eur., USP-NF, JP: Crospovidone type A |
| | ● | ● | ● | ● | ● | ● | Kollidon® CL-SF | P Superdisintegrant recommended for small tablets, MUPS and ODTs, providing very pleasant mouthfeel due to its super-fine particles. | Ph. Eur., USP-NF, JP: Crospovidone type B |

Core formulation

| Functionality | Process | | | Dosage form | | | Product | Description | Monograph title*/ Chemical name |
|----------------------------|--------------------|---|-----------------|----------------------|---|-----|--------------------------------|--|--|
| | Direct compression | Dry granulation (incl. roller compaction) | Wet granulation | Tablets and capsules | Particles (granules, pellets, and MUPS) | ODT | | | |
| Sustained Release Matrices | ● | ● | ● | ● | ● | | Kolliwax® HCO | Lipophilic sustained release matrix indicated for highly soluble and sensitive APIs | Ph. Eur.: Castor oil, hydrogenated; USP-NF: Hydrogenated castor oil; JP: Hydrogenated oil |
| | ● | ● | ● | ● | ● | | Kolliwax® SA Fine | Lipophilic sustained release matrix indicated for highly soluble and sensitive APIs | Ph. Eur., USP-NF, JP: Stearyl alcohol |
| | ● | ● | ● | ● | ● | | Kolliwax® S Fine | Lipophilic sustained release matrix indicated for highly soluble and sensitive APIs | Ph. Eur., USP-NF, JP: Stearic acid 50 |
| | ● | ● | ● | ● | ● | | Kollidon® SR | Highly compressible and flowable hydrophobic matrix designed for robust sustained release formulations made by direct compression and melt granulation. | 80% PVAc, 19% Povidone, 0.8% SLS, 0.2% Silica |
| Coproprocessed Excipients | ● | ● | ● | ● | ● | ● | Ludiflash® | Coproprocessed excipient with excellent tableting properties, superior mouthfeel, and rapid disintegration, ideal for applications requiring quick dissolving in the mouth, such as ODTs. | 90% Mannitol, 5% Crospovidone, 5% Polyvinyl acetate (from Kollicoat SR 30 D) |
| | ● | ● | | ● | ● | | Ludipress® | Coproprocessed excipient containing filler, binder and disintegrant that simplifies direct compression formulations. | 93% Lactose, 3.5% Povidone, 3.5% Crospovidone |
| | ● | ● | | ● | ● | | Ludipress® LCE | Coproprocessed excipient containing filler and binder with optimal flowability for lozenges, chewables and effervescent tablets. | 96.5% Lactose, 3.5% Povidone |
| | ● | ● | | ● | ● | | Kollitab® DC 87L | All-in-one coproprocessed excipient for fast and cost-effective direct compression and continuous manufacturing processes. Indicated for low and high drug loads due to its excellent blending and flowing properties. | 87% Lactose, 3% Ethylene glycol and vinyl alcohol graft copolymer, 9% Crospovidone, 1% Sodium stearyl fumarate |
| Surfactants | | | ● | ● | ● | | Kolliphor® SLS |  Wetting agent and surfactant particularly suitable for wet and melt granulations. | Ph. Eur.: Sodium laurilsulfate; USP-NF, JP: Sodium lauryl sulfate |
| | ● | ● | ● | ● | ● | | Kolliphor® SLS Fine |  Wetting agent, surfactant, and lubricant, particularly suitable for direct compression due to its fine size | Ph. Eur.: Sodium laurilsulfate; USP-NF, JP: Sodium lauryl sulfate |
| | ● | ● | | ● | ● | ● | Kolliphor® P 188 micro Geismar | Its very fine particle size makes it an effective dissolution enhancer, lubricant, and wetting agent in direct compression. | Ph. Eur., USP-NF: Poloxamer 188; JPE: Polyoxyethylene (160), polyoxypropylene (30) glycol** |
| | ● | ● | | ● | ● | ● | Kolliphor® P 407 micro Geismar | Its very fine particle size makes it an effective dissolution enhancer, lubricant, and wetting agent in direct compression. | Ph. Eur., USP-NF: Poloxamer 407; JPE: Polyoxyethylene (196), polyoxypropylene (67) glycol** |

Core formulation

| Functionality | Process | | | Dosage form | | | Product | Description | Monograph title*/ Chemical name |
|----------------------------|--------------------|---|-----------------|----------------------|---|-----|---|---|---|
| | Direct compression | Dry granulation (incl. roller compaction) | Wet granulation | Tablets and capsules | Particles (granules, pellets, and MUPS) | ODT | | | |
| Surfactants (continued) | | | ● | ● | ● | ● | Kolliphor® P 188 Geismar | Dissolution enhancer, lubricant, and wetting agent particularly suitable for wet and melt granulations. | Ph. Eur., USP-NF: Poloxamer 188; JPE: Polyoxyethylene (160), polyoxypropylene (30) glycol** |
| | | | ● | ● | ● | ● | Kolliphor® P 407 Geismar | Dissolution enhancer, lubricant, and wetting agent particularly suitable for wet and melt granulations. | Ph. Eur., USP-NF: Poloxamer 407; JPE: Polyoxyethylene (196) polyoxypropylene (67) glycol** |
| Lubricants | ● | ● | ● | ● | | | Kolliphor® SLS Fine  | Fine surfactant and hydrophilic lubricant particularly suitable for poor soluble drugs. | Ph. Eur.: Sodium laurilsulfate; USP-NF, JP: Sodium lauryl sulfate |
| | ● | ● | ● | ● | ● | ● | Kolliphor® P 188 micro Geismar | Micronized and hydrophilic lubricant & surfactant particularly suitable for poor soluble drugs. | Ph. Eur., USP-NF: Poloxamer 188; JPE: Polyoxyethylene (160) polyoxypropylene (30) glycol** |
| | ● | ● | ● | ● | ● | ● | Kolliphor® P 407 micro Geismar | Micronized and hydrophilic lubricant & surfactant particularly suitable for poor soluble drugs. | Ph. Eur., USP-NF: Poloxamer 407; JPE: Polyoxyethylene (196) polyoxypropylene (67) glycol** |
| | ● | ● | ● | ● | ● | | Kolliwax® S Fine  | Lipophilic lubricant. Particularly suitable for sensitive APIs. | Ph. Eur., USP-NF, JP: Stearic acid 50 |
| | ● | ● | ● | ● | ● | | Kolliwax® HCO | Lipophilic lubricant. Particularly suitable for sensitive APIs. | Ph. Eur., Castor oil, hydrogenated, USP-NF: Hydrogenated castor oil, JPE: Hydrogenated oil |



Coating formulation

| Functionality | Process | | Release | | | Dosage form | | Product | Description | Monograph title*/ Chemical name |
|------------------------------------|---------|-----------------|---------|---------|-----------|----------------------|---|----------------------------|--|---|
| | Aqueous | Organic Solvent | Instant | Enteric | Sustained | Tablets and capsules | Particles (granules, pellets, and MUPS) | | | |
| Immediate Release Film Coatings | ● | | ● | | | ● | ● | Kollicoat® IR | Flexible, water-soluble, and low-viscosity polymer, allowing high solids content. Efficient coating with excellent adhesiveness and film-forming properties. It is recommended as an aesthetic film, sub-coating, drug layering polymer, and pore former in sustained-release formulations | Ph. Eur.: Macrogol poly(vinyl alcohol) grafted copolymer; USP-NF: Ethylene glycol and vinyl alcohol graft copolymer; JPE: Polyvinyl alcohol-polyethylene glycol graft copolymer |
| | ● | | ● | | | ● | ● | Kollicoat® Protect | Instant-release film coating for sensitive drugs that require moisture and oxygen protection. | Excipient based on Kollicoat® IR and polyvinyl alcohol |
| | ● | | ● | | | ● | ● | Kollicoat® Smartseal 30 D | 30% polymer aqueous dispersion for taste masking and moisture protection. Rapidly dissolves at a pH below 5, providing immediate drug release. | Methyl-methacrylate – diethylaminoethyl methacrylate co-polymer |
| | ● | ● | ● | | | ● | ● | Kollicoat® Smartseal 100 P | Suitable for aqueous and solvent coating; powder is re-dispersible in water after neutralization. Rapidly dissolves at a pH below 5, providing immediate drug release in the stomach. | Methyl-methacrylate – diethylaminoethyl methacrylate co-polymer |
| Sustained Release Film Coating | ● | | | | ● | ● | ● | Kollicoat® SR 30 D | Sustained release film coating at a 30% polymer aqueous dispersion. pH-independent and highly elastic film-former suitable for coating small particles, pellets, granules and tablets. | Ph. Eur.: Poly(vinyl acetate) dispersion 30 per cent; USP-NF: Polyvinyl acetate dispersion |





* Monograph references were updated at time of printing, please visit us online for the latest status

Coating formulation



| Functionality | Process | | Release | | | Dosage form | | Product | Description | Monograph title*/ Chemical name |
|-------------------------------|---------|-----------------|---------|---------|-----------|----------------------|---|----------------------------|---|---|
| | Aqueous | Organic Solvent | Instant | Enteric | Sustained | Tablets and capsules | Particles (granules, pellets, and MUPS) | | | |
| Enteric-Release Film Coatings | ● | | | ● | | ● | ● | Kollicoat® MAE 30 DP | Enteric coating with release above pH 5.5, available as a 30% aqueous polymer dispersion. | Ph. Eur.: Methacrylic acid – ethyl acrylate copolymer (1:1) dispersion 30 per cent; USP-NF: Methacrylic acid copolymer dispersion; JPE: Methacrylic acid copolymer LD |
| | ● | | | ● | | ● | ● | Kollicoat® MAE 100 P | Enteric coating with release above pH 5.5, available as partially preneutralized powder saving you time in the neutralization step. | Ph. Eur.: Methacrylic acid – ethyl acrylate copolymer (1:1), type B; USP-NF: Partially-neutralized methacrylic acid and ethyl acrylate copolymer |
| | ● | ● | | ● | | ● | ● | Kollicoat® MAE 100-55 | Non-neutralized, fast redispersing, dust-free powder grade for aqueous and organic enteric film coating with release above pH 5.5. | Ph. Eur.: Methacrylic acid – ethyl acrylate copolymer (1:1), type A; USP-NF: Methacrylic acid and ethyl acrylate copolymer; JPE: Dried methacrylic acid copolymer LD |
| | ● | ● | | ● | | ● | ● | Kollicoat® MAE 100-55 Fine | Non-neutralized, fast redispersing, and fine powder grade for aqueous and organic enteric film coating with release above pH 5.5. | Ph. Eur.: Methacrylic acid – ethyl acrylate copolymer (1:1), type A; USP-NF: Methacrylic acid and ethyl acrylate copolymer; JPE: Dried methacrylic acid copolymer LD |

* Monograph references were updated at time of printing, please visit us online for the latest status

Coating formulation

| Functionality | Process | | Release | | | Dosage form | | Product | Description | Monograph title*/ Chemical name |
|-----------------------------|---------|-----------------|---------|---------|-----------|----------------------|---|---|--|--|
| | Aqueous | Organic Solvent | Instant | Enteric | Sustained | Tablets and capsules | Particles (granules, pellets, and MUPS) | | | |
| Plasticizers | | | | | | ● | ● | Kollisolv® GTA | Plasticizer particularly suitable for film coatings. | Triacetin |
| | | | | | | ● | ● | Kollisolv® PG | Liquid hydrophilic plasticizer. | Ph. Eur., JP, FCC, USP-NF: Propylene glycol |
| | | | | | | ● | ● | Kollisolv® PEG 300 | Liquid plasticizer commonly used in film coatings. Also used as solvent in liquid formulations. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol, JPE: Macrogol 300; FCC: Polyethylene glycols |
| | | | | | | ● | ● | Kollisolv® PEG 400 | Liquid plasticizer commonly used in film coatings. Also used as solvent in liquid formulations. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol; JP: Macrogol 400; FCC: Polyethylene glycol |
| | | | | | | ● | ● | Kollisolv® PEG 1450 | Plasticizer commonly used in film coatings. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol |
| | | | | | | ● | ● | Kollisolv® PEG 8000 | Plasticizer commonly used in film coatings. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol |
| | | | | | | ● | ● | Kollisolv® P 124 Geismar | Liquid plasticizer commonly used in tablet coatings. Also used as solubilizer and solvent in liquid formulations. | Ph. Eur., USP-NF: Poloxamer 124; JPE: Polyoxyethylene (20) polyoxypropylene (20) glycol ** |
| | | | | | | ● | ● | Kolliphor® PS 20 |  Non-ionic solubilizer, emulsifier, co-emulsifier and plasticizer. | Ph. Eur., USP-NF, JPE: Polysorbate 20 |
| | | | | | | ● | ● | Kolliphor® PS 60 |  Non-ionic solubilizer, emulsifier, co-emulsifier and plasticizer. | Ph. Eur., USP-NF, JPE: Polysorbate 60 |
| | | | | | | ● | ● | Kolliphor® PS 80 |  Non-ionic solubilizer, emulsifier, co-emulsifier and plasticizer. | Ph. Eur., USP-NF, JPE: Polysorbate 80 |
| | | | | | ● | ● | Kolliphor® SML 20 |  Liquid plasticizer. Also used as emulsifier and co-emulsifier in oral formulations. | Ph.Eur.: Sorbitan Laurate | |
| Taste-Masking Film Coatings | ● | | ● | | | ● | ● | Kollicoat® Smartseal 30 D | Highly effective taste masking film-coating in a 30% polymeric aqueous dispersion, providing a final pleasant taste and smell of drug product. | Methyl-methacrylate – diethylaminoethyl methacrylate co-polymer |
| | ● | ● | ● | | | ● | ● | Kollicoat® Smartseal 100 P | Highly effective taste masking film-coating in powder. Suitable for aqueous and organic formulations. | Methyl-methacrylate – diethylaminoethyl methacrylate co-polymer |
| | ● | | | | ● | ● | ● | Kollicoat® SR 30 D | Applying a thin coating layer on the surfaces of pellets, granules, or tablets provides basic taste-masking properties by reducing the drug's contact with the taste buds. | Ph. Eur.: Poly(vinyl acetate) dispersion 30 per cent; USP-NF: Polyvinyl acetate dispersion |

Coating formulation

| Functionality | Product | Description | Monograph title*/Chemical name |
|------------------------|--|--|---|
| Film-Coating Additives | Kollocoat® IR | Water-soluble polymer with excellent adhesion and flexibility, acting as a pore former in sustained-release film coatings. | Ph. Eur.: Macrogol poly(vinyl alcohol) grafted copolymer; USP-NF: Ethylene glycol and vinyl alcohol graft copolymer; JPE: Polyvinyl alcohol-polyethylene glycol graft copolymer |
| | Kollidon® VA 64 | Water and organic-soluble polymer used to enhance film adhesion, as a sub-coating, and serve as a pore former in sustained-release formulations | Ph. Eur., USP-NF: Copovidone; JPE: Copolyvidone |
| | Kollidon® 12 PF | Water and organic-soluble polymer acting as a pore former in sustained release film-coatings. | Ph. Eur., USP-NF, JP: Povidone |
| | Kollidon® 17 PF | Water and organic-soluble polymer acting as a pore former in sustained release film-coatings. | Ph. Eur., USP-NF, JP: Povidone |
| | Kollidon® 30 ^Δ | Water and organic-soluble polymer acting as a pore former in sustained release film-coatings. | Ph. Eur., USP-NF, JP: Povidone |
| | Kolliwax® GMS II  | Anti-tacking agent in combination with polysorbate 80. | Ph. Eur.: Glycerol monostearate 40-55 (type II), USP-NF: Mono- and di-glycerides |
| | Kolliphor® PS 80 | Emulsifier and co-emulsifier in oral formulations. | Ph. Eur., USP-NF, JPE: Polysorbate 80 |
| | Kolliwax® HCO | Hydrophobic wax acting as a moisture barrier. It can also be used to modulate the initial drug release in combination with a film-coating polymer. | Ph. Eur.: Castor oil, hydrogenated; USP-NF: Hydrogenated castor oil; JP: Hydrogenated oil |
| | Kolliwax® S Fine  | Hydrophobic wax acting as moisture barrier. It can also be used to modulate the initial drug release in combination with a film-coating polymer | Ph. Eur., USP-NF, JP: Stearic acid 50 |



Topicals

BASF offers an unparalleled portfolio of pharmaceutical grade excipients intended for topical and transdermal use. We empower our customers to create a broad range of semi-solid formulations suitable for a variety of applications.












We are committed to maintaining the highest level of quality across the product spectrum. Our portfolio offers a variety of functional, RSPO-certified, reduced-carbon footprint excipients including penetration enhancers, viscosity modifiers, drug solubilizers, surfactants, and gelling agents to support the development of dermatological product applications. BASF's team of internationally recognized skin delivery experts is dedicated to working closely with you. Improve the health and well-being of patients through the enhancement of dermal drug delivery, semi-solid microstructure, mildness, and sensory.









<https://pharma.basf.com/solutions/topicals>









Creams, foams, ointments and gels

| Functionality | Product | Delivery form | | | | Description | Monograph title*/Chemical name |
|----------------------------|---|---------------|-------|-----------|------|---|--|
| | | Creams | Foams | Ointments | Gels | | |
| Emollients | Kollicream® 3 C  | ● | ● | ● | ● | Medium spreadability emollient. Extremely mild solvent for lipophilic drugs. Enhances API skin penetration. | Ph. Eur.: Cocoyl caprylocaprate, USP-NF: Cocoyl Caprylocaprate |
| | Kollicream® CP 15  | ● | | ● | | Solid, slow spreading emollient with rich skinfeel. Solvent for lipophilic drugs. | Ph. Eur.: Cetyl palmitate |
| | Kollicream® DO  | ● | ● | ● | ● | Medium spreadability. Solvent for lipophilic drugs. Enhances skin penetration. | Ph. Eur.: Decyl oleate |
| | Kollicream® IPM  | ● | ● | ● | ● | Low viscosity emollient that promotes a fresh sensory effect. Ideal for light and highly spreadable products | Ph. Eur., USP-NF: Isopropyl myristate |
| | Kollicream® OA  | ● | ● | ● | ● | Versatile, medium spreadability emollient and solvent for lipophilic drugs. | Ph. Eur., USP-NF: Oleyl alcohol |
| | Kollicream® OD  | ● | ● | ● | ● | Emollient with medium spreadability. Solvent for lipophilic drugs. Enhances skin penetration. Effective in exceptionally wide pH range. | Ph. Eur., USP-NF: Octyldodecanol |
| Skin penetration enhancers | Kollicream® DO  | ● | ● | ● | ● | Skin penetration enhancer functions as an emollient with medium spreadability. | Ph. Eur.: Decyl oleate |
| | Kollicream® IPM  | ● | ● | ● | ● | Fast spreading emollient and skin penetration enhancer for hydrophilic drugs. | Ph. Eur., USP-NF: Isopropyl myristate |
| | Kollicream® 3C  | ● | ● | ● | ● | Excellent at enhancing drug skin penetration while maintaining mildness. Suitable for a wide range of topical applications. | Ph. Eur., USP-NF: Cocoyl caprylocaprate |
| | Kollicream® OA  | ● | ● | ● | ● | Skin penetration enhancer functions as an emollient with medium spreadability. | Ph. Eur., USP-NF: Oleyl alcohol |
| | Kollicream® OD  | ● | ● | ● | ● | Medium spreadability solvent for lipophilic drugs, and effective at increasing skin penetration. Suitable over an exceptionally wide pH range | Ph. Eur., USP-NF: Octyldodecanol |
| | Kollisolv® PG | ● | ● | ● | ● | Skin penetration enhancer and solvent. | Ph. Eur., USP-NF, JP, FCC: Propylene glycol |
| | Kollisolv® PYR | ● | ● | ● | ● | Versatile solvent with broad miscibility. | Ph. Eur.: Pyrrolidone |

Creams, foams, ointments and gels

| Functionality | Product | Delivery form | | | | Description | Monograph title*/Chemical name |
|-----------------------|--|---------------|-------|-----------|------|---|--|
| | | Creams | Foams | Ointments | Gels | | |
| Solubilizers | Kollisolv® MCT 70  | ● | ● | ● | ● | Oily solvent for some lipophilic drugs. Water barrier-repairing, emollient film-former on skin. | Ph. Eur.: Triglycerides, medium-chain USP-NF: Medium-chain triglycerides |
| | Kollisolv® PEG 300 | ● | ● | ● | ● | Solubilizer for drugs. Forms anhydrous, hydrophilic ointments in conjunction with higher mol. weight PEG. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol, JPE: Macrogol 300; FCC: Polyethylene glycols |
| | Kollisolv® PEG 300 G | ● | ● | ● | ● | Solubilizer for drugs. Forms anhydrous, hydrophilic ointments in conjunction with higher mol. weight PEG. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol |
| | Kollisolv® PEG 400 | ● | ● | ● | ● | Solubilizer for drugs. Forms anhydrous, hydrophilic ointments in conjunction with higher mol. weight PEG. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol; JP: Macrogol 400; FCC: Polyethylene glycols |
| | Kollisolv® PEG 400 G | ● | ● | ● | ● | Solubilizer for drugs. Forms anhydrous, hydrophilic ointments in conjunction with higher mol. weight PEG. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol |
| | Kollisolv® GTA | ● | ● | | ● | Versatile water or oil miscible solvent. | Triacetin |
| | Kollisolv® PG | ● | ● | ● | ● | Versatile hydrophilic solvent and humectant. | Ph. Eur., USP-NF, JP, FCC: Propylene glycol |
| Non-ionic emulsifiers | Kolliphor® CS 12  | ● | ● | | | Solid, non-ionic emulsifier for oil/water emulsions. Suitable over a wide pH range for challenging formulations | Ph. Eur.: Macrogol cetostearyl ether 12 |
| | Kolliphor® CS 20  | ● | ● | | | Solid, non-ionic emulsifier for oil/water emulsions. Works synergistically with structure factors to enhance product stability. | Ph. Eur.: Macrogol cetostearyl ether 20, USP-NF: Polyoxyl 20 cetostearyl ether |
| | Kolliphor® EL | ● | | | | Non-ionic emulsifier for oil/water emulsions. Also an effective solubilizer that can improve API stability | Ph. Eur.: Macrogolglycerol ricinoleate; USP-NF: Polyoxyl 35 castor oil; JPE: Polyoxyl 35 castor oil |
| | Kolliphor® HS 15 | ● | | | | A highly effective solubilizer and emulsifying agent for poorly soluble APIs | Ph. Eur.: Macrogol 15 hydroxystearate; USP-NF: Polyoxyl 15 hydroxystearate |
| | Kolliphor® PS 20  | ● | ● | | ● | Liquid, non-ionic emulsifier uniquely suitable for weakly lipophilic drugs and oils. | Ph. Eur., USP-NF: Polysorbate 20 |
| | Kolliphor® PS 60  | ● | ● | | ● | Semi-solid, highly versatile non-ionic emulsifier for oil/water emulsions; also an effective foam stabilizer. | Ph. Eur., USP-NF, JPE: Polysorbate 60 |
| | Kolliphor® PS 80  | ● | ● | | ● | Liquid, non-ionic emulsifier suitable for a wide range of drugs and oil/water emulsion applications. | Ph. Eur., USP-NF: Polysorbate 80 |
| | Kolliphor® RH 40 | ● | ● | | ● | Multi-purpose oil/water emulsifier and solubilizer; effective at forming self-emulsifying systems when used as a co-emulsifier. | Ph. Eur.: Macrogolglycerol hydroxystearate, USP-NF: Polyoxyl 40 hydrogenated castor oil |

Creams, foams, ointments and gels

| Functionality | Product | Delivery form | | | | Description | Monograph title*/Chemical name |
|-----------------------|---|---------------|-------|-----------|------|---|--|
| | | Creams | Foams | Ointments | Gels | | |
| Non-ionic emulsifiers | Kollisol® P 124 Geismar** | ● | ● | | ● | Liquid amphiphilic co-polymer; effective at forming light, airy foams. | Ph. Eur., USP-NF: Poloxamer 124; JPE: Polyoxyethylene (20) polyoxypropylene (20) glycol |
| | Kolliphor® P 188 Geismar | ● | ● | | ● | Solid amphiphilic co-polymer; a multi-purpose drug solubilizer, emulsifier, and foaming agent. Very mild. | Ph. Eur., USP-NF: Poloxamer 188; JPE: Polyoxyethylene (160) polyoxypropylene (30) glycol |
| | Kolliphor® P 338 Geismar | ● | ● | | ● | Solid amphiphilic co-polymer, drug solubilizer, emulsifier, and viscosity modifier. | Ph. Eur., USP-NF: Poloxamer 338 |
| | Kolliphor® P 407 Geismar | ● | ● | | ● | Extremely versatile solid amphiphilic co-polymer. Effective as a co-emulsifier, drug solubilizer, gel former, and emulsifier. | Ph. Eur., USP-NF, JPE, Poloxamer 407, Polyoxyethylene (196) polyoxypropylene (67) glycol |
| | Kolliphor® SML 20  | ● | ● | | ● | Non-ionic emulsifier for W-O emulsions; effective co-emulsifier for challenging formulation tasks. | Ph. Eur. : Sorbitan Laurate |
| Anionic emulsifiers | Kolliphor® SLS  | | ● | | | Anionic emulsifier used for improving foaming capacity and thickness of semi-solid formulations. | Ph. Eur.: Sodium laurilsulfate; USP-NF, JP: Sodium lauryl sulfate |
| | Kolliphor® SLS Fine  | | ● | | | Finer particles of Kolliphor® SLS for more controlled and efficient solubilization. | Ph. Eur.: Sodium laurilsulfate; USP-NF, JP: Sodium lauryl sulfate |
| | Kolliphor® CSS  | ● | ● | | | Anionic emulsifier effective for forming gentle, light cleansing solutions and foams; works synergistically with other emulsifiers. | Ph. Eur.: Sodium cetostearyl sulfate |
| | Kolliphor® CS A  | ● | | | | Anionic emulsifier and structuring agent combination for creams and lotions. Self emulsifying wax. | Ph. Eur.: Cetostearyl alcohol (type A), emulsifying |
| | Kolliphor® CSL  | ● | | | | A mixture of emulsifier and waxes that is self-emulsifying and consistency building. It can be used as an easy-to-use base for dermatological creams. | Mixture of cetyl stearyl alcohol, sodium lauryl sulfate and sodium cetyl stearyl sulfate |










 RSPO (Roundtable on Sustainable Palm Oil) certified

*Monograph references were updated at time of printing, please visit us online for the latest status

**The product meets the test requirements of the current monograph of "Polyoxyethylene (20) Polyoxypropylene (20) Glycol" JPE, containing d,1-alpha tocopherol

***The product meets the test requirements of the current monograph of "Polyoxyethylene (160) Polyoxypropylene (30) Glycol" JPE, containing BHT




Creams, foams, ointments and gels

| Functionality | Product | Delivery form | | | | Description | Monograph title*/Chemical name |
|--|--|---------------|-------|-----------|------|---|---|
| | | Creams | Foams | Ointments | Gels | | |
| Viscosity modifiers and structuring agents | Kolliwax® MA  | ● | | ● | ● | Consistency factor with low melting point. Soft sensory effect. | USP-NF: Myristyl alcohol |
| | Kolliwax® CA  | ● | | ● | ● | Structure-building consistency factor for semi-solids. Viscosity regulator. | Ph. Eur., USP-NF: Cetyl alcohol |
| | Kolliwax® SA  | ● | | ● | ● | Structure-building consistency factor for semi-solids. Viscosity regulator. Higher melting point. | Ph. Eur., USP-NF, JP: Stearyl alcohol |
| | Kolliwax® CSA 50  | ● | ● | ● | ● | Structure-building consistency factor for semi-solids. Viscosity regulator for rich, care-feeling products. | Ph. Eur., USP-NF, JPE: Cetostearyl alcohol |
| | Kolliwax® CSA 70  | ● | | ● | ● | Structure-building consistency factor for semi-solids. Viscosity regulator for light, higher-spreading products. | Ph. Eur.: Cetostearyl alcohol |
| | Kolliphor® CS A  | ● | | | | Anionic emulsifier and consistency factor combination for creams and lotions. Self emulsifying wax. | Ph. Eur.: Cetostearyl alcohol (type A), emulsifying |
| | Kolliphor® CSL  | ● | | ● | ● | A mixture of emulsifier and waxes that is self-emulsifying and consistency building. It can be used as an easy-to-use base for dermatological creams. | Mixture of cetyl stearyl alcohol, sodium lauryl sulfate and sodium cetyl stearyl sulfate |
| | Kolliwax® GMS II  | ● | | ● | ● | Improves semi-solid viscosity and stability. Can mitigate stickiness or greasiness. | Ph. Eur.: Glycerol monostearate 40-55 (type II); USP-NF: Mono- and di-glycerides |
| | Kolliwax® HCO | ● | | ● | ● | Improves stability; high melting point and retention on skin; applies with little whiteness. | Ph. Eur.: Castor oil, hydrogenated; USP-NF: Hydrogenated castor oil; JP: Hydrogenated oil |
| | Kolliwax® S  | ● | | ● | | Structure-building consistency factor with dry feel; deposits a crystalline barrier on the surface of the skin. | Ph. Eur., USP-NF, JP: Stearic acid 50 |
| | Kollisolv® PEG 1000 | ● | ● | ● | ● | Forms anhydrous, hydrophilic ointments in combination with low mol. weight PEG. | Ph. Eur.: Macrogols, Polyethylene glycol 1000 |
| | Kollisolv® PEG 1450 | ● | | ● | | Forms anhydrous, hydrophilic ointments in combination with low mol. Weight PEGs; also used to formulate hydrophilic stick-balm products. | USP-NF: Polyethylene glycol 1450 |
| | Kollisolv® PEG 8000 | ● | | ● | | Forms anhydrous, hydrophilic ointments in combination with low mol. weight PEG. | Ph. Eur.: Macrogols, Polyethylene glycol 8000 |
| Gelling agents | Kolliphor® P 188 Geismar | ● | ● | | ● | Forms clear, thermo-reversible gels at higher concentrations-temperatures. Improves drug solubility and functions as a wetting agent. | Ph. Eur., USP-NF: Poloxamer 188; JPE: Polyoxyethylene (160) polyoxypropylene (30) glycol |
| | Kolliphor® P 338 Geismar | ● | ● | | ● | Forms clear, thermo-reversible gels at higher concentrations-temperatures. Effective at forming solutions that gel near body temperature. | Ph. Eur., USP-NF: Poloxamer 338 |
| | Kolliphor® P 407 Geismar | ● | ● | | ● | Forms robust, clear, thermo-reversible gels at high concentrations; can be reverted to a liquid state at low temperatures. | Ph. Eur., USP-NF, JPE, Poloxamer 407, Polyoxyethylene (196) polyoxypropylene (67) glycol |














Topical polymeric films

| Functionality | Product | Description | Monograph title*/Chemical name |
|---------------|---------------------------|---|---|
| Film formers | Kollidon® 90 Evo | P Film former and viscosifying agent in aqueous formulations. Drug solubilizer. | Ph. Eur., USP-NF, JP: Povidone |
| | Kollidon® VA 64 | Sprayable film former; drug solubilizer and matrix former in HME or solvent cast films. | Ph. Eur., USP-NF: Copovidone; JPE: Copolyvidone |
| | Kollidon® SR | Sprayable polymer film former; effective for targeted drug delivery, with good film adhesion and flexibility. | 80% PVAc, 19% povidone, 0.8% SLS, 0.2% silica |
| | Kollidon® 30 ^Δ | P Polymeric film former. Flexible. | Ph. Eur., USP-NF, JP: Povidone |
| | Kollocoat® IR | Polymeric film former. Flexible. | Ph. Eur.: Macrogol poly(vinyl alcohol) grafted copolymer; USP-NF: Ethylene glycol and vinyl alcohol graft copolymer; JPE: Polyvinyl alcohol-polyethylene glycol graft copolymer |
| | Kollocoat® SR 30 D | Sprayable polymeric film former; flexible and wash-resistant; improves drug retention on skin surface. | Ph. Eur.: Poly(vinyl acetate) dispersion 30 per cent; USP-NF: Polyvinyl acetate dispersion, USP-NF: Polyvinyl acetate dispersion |
| | Soluplus® | Forms solid solutions, increasing solubility and bioavailability. Extrudable into films. | Polyvinyl caprolactam – polyvinyl acetate – polyethylene glycol graft copolymer |
| Plasticizers | Kollisolv® PEG 400 | Film plasticizer. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol; JP: Macrogol 400; FCC: Polyethylene glycols |
| | Kollisolv® PEG 400 G | Film plasticizer. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol |
| | Kollisolv® PEG 1450 | Film plasticizer. | USP-NF: Polyethylene glycol |
| | Kollisolv® PG | Film plasticizer and co-surfactant. | Ph. Eur., USP-NF, JP, FCC: Propylene glycol |
| | Kolliphor® P 188 Geismar | Versatile plasticizer and solubilizer for polymeric films. | Ph. Eur., USP-NF: Poloxamer 188; JPE: Polyoxyethylene (160) polyoxypropylene (30) glycol |
| | Kollisolv® GTA | Polymeric film plasticizer; versatile water or oil miscible solvent. | Triacetin |

Transdermal patches

| Functionality | Product | Description | Monograph title*/Chemical name |
|----------------|--|--|---|
| Matrix formers | Kollocoat® MAE 100 P | Matrix polymer. | Ph. Eur.: Methacrylic acid – ethyl acrylate copolymer (1:1), type B; USP-NF: Partially-neutralized methacrylic acid and ethyl acrylate copolymer |
| | Kollidon® CL-M | Used as transdermal drug delivery aid and may improve drug solubilization. | Ph. Eur., USP-NF, JP, Crospovidone |
| | Kollidon® SR | Matrix polymer. | 80% PVAc, 19% povidone, 0.8% SLS, 0.2% silica |
| Solubilizers | Kolliphor® EL | Solubilizer e.g. for microneedles, approved for injectable formulations. | Ph. Eur.: Macroglycerol ricinoleate; USP-NF: Polyoxyl 35 castor oil; JPE: Polyoxyl 35 castor oil |
| | Kolliphor® HS 15 | Solubilizer e.g. for microneedles, approved for injectable formulations. | Ph. Eur.: Macrogol 15 hydroxystearate; USP-NF: Polyoxyl 15 hydroxystearate |
| | Kollcream® IPM |  Skin penetration enhancer. Solvent for lipophilic drugs. | Ph. Eur., USP-NF: Isopropyl myristate |
| | Kollcream® OA |  Skin penetration enhancer. Solvent for lipophilic drugs. | Ph. Eur., USP-NF: Oleyl alcohol |
| | Kollcream® OD |  Potential solubilizer of lipophilic APIs and a penetration enhancer. | Ph. Eur., USP-NF: Octyldodecanol |
| | Kollisolv® PG | Solvent for lipophilic actives. Prevents crystallization of actives. | Ph. Eur., USP-NF, JP, FCC: Propylene glycol |
| | Kollisolv® GTA | Miscible in both oil and water. Functions as a plasticizer for polymeric films. | Ph. Eur., USP-NF: Triacetin |
| | Kolliphor® P 188 Geismar | Inert, biocompatible, amphiphilic polymer, approved for injectable applications. | Ph. Eur., USP-NF: Poloxamer 188; JPE: Polyoxyethylene (160) polyoxypropylene (30) glycol |
| | Kollidon® 12 PF Kollidon® 17 PF | P Endotoxin tested with compound related validated limits; P Particularly suitable for dissolvable microneedles. | Ph. Eur., USP-NF, JP: Povidone |
| | Kollidon® CL-M | Used as transdermal drug delivery aid and may improve drug solubilization. | Ph. Eur., USP-NF, JP, Crospovidone |
| | Kollidon® 25 | P Drug solubilizers (via complexation). | Ph. Eur., USP-NF, JP: Povidone |
| | Kollidon® 30 ^Δ Kollidon® 30 LP | P P Drug solubilizer with low peroxide option. | Ph. Eur., USP-NF, JP: Povidone |
| | Kollidon® 90 Evo | P Drug solubilizer and delivery aid in transdermal patches. | Ph. Eur., USP-NF, JP: Povidone |
| | Soluplus® | Forms solid solutions, increasing solubility and bioavailability. Extrudable into films. | Polyvinyl caprolactam – polyvinyl acetate – polyethylene glycol graft copolymer |
| | Kollidon® VA 64 | Drug solubilizer and matrix former in extruded or solvent cast films. | Ph. Eur., USP-NF: Copovidone; JPE: Copolyvidone |

Suppositories

| Functionality | Product | Description | Monograph title*/Chemical name |
|--|---------------------|--|---|
| Viscosity modifiers and structuring agents | Kolliwax® CA |  Structure-building consistency factor; C16 fatty alcohol. | Ph. Eur., USP-NF: Cetyl alcohol |
| | Kolliwax® CSA 50 |  Blend of C16 & C18 fatty alcohols used for stabilizing anhydrous formulations. | Ph. Eur., USP-NF, JPE: Cetostearyl alcohol |
| | Kolliwax® CSA 70 |  Blend of C16 & C18 fatty alcohols used for stabilizing anhydrous formulations. | Ph. Eur.: Cetostearyl alcohol |
| | Kolliwax® SA |  Structure-building consistency factor; C18 fatty alcohol. | Ph. Eur., USP-NF, JP: Stearyl alcohol |
| | Kollisolv® PEG 1000 | Builds consistency in suppositories when mixed with low MW liquid PEGs. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol 1000 |
| | Kollisolv® PEG 1450 | Builds consistency in suppositories when mixed with low MW liquid PEGs. | USP-NF: Polyethylene glycol 1450 |
| | Kollisolv® PEG 3350 | Builds consistency in suppositories when mixed with low MW liquid PEGs. | USP-NF: Polyethylene glycol 3350 |
| | Kollisolv® PEG 8000 | Builds consistency in suppositories when mixed with low MW liquid PEGs. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol 8000 |
| | Kollidon® CL | P Matrix former. | Ph. Eur., USP-NF, JP: Crospovidone type A |
| | Novata® B PH |  Hard fat for suppository matrix, melting point 33.5 – 35.5 deg C. | Ph. Eur.: Hard fat |
| | Novata® BC PH |  Hard fat for suppository matrix, melting point 33 – 34.5 deg C. | Ph. Eur.: Hard fat |
| | Novata® BCF PH |  Hard fat for suppository matrix, melting point 35 – 37 deg C. | Ph. Eur.: Hard fat |
| Solubilizers | Kollisolv® MCT 70 |  Solubilizer for lipophilic drugs. Penetration enhancer. Lubricant. | Ph. Eur.: Triglycerides, medium-chain, USP-NF: Medium chain triglycerides |
| | Kollisolv® PG | Solubilizes and aids in skin penetration of lipophilic actives. | Ph. Eur., USP-NF, JP, FCC: Propylene glycol |
| | Kollicream® IPM |  Solubilizer for lipophilic actives. | Ph. Eur., USP-NF: Isopropyl myristate |
| | Kollicream® OD |  Potential solubilizer of lipophilic APIs and a penetration enhancer. | Ph. Eur., USP-NF: Octyldodecanol |
| Emulsifiers | Kolliphor® PS 20 |  Non-ionic, hydrophilic emulsifier. | Ph. Eur., USP-NF: Polysorbate 20 |
| | Kolliphor® PS 60 |  Non-ionic, hydrophilic emulsifier. | Ph. Eur., USP-NF, JPE: Polysorbate 60 |
| | Kolliphor® PS 80 |  Non-ionic, hydrophilic emulsifier. | Ph. Eur., USP-NF: Polysorbate 80 |

Parenterals

The parenteral application requires excipients of the highest quality standards. Solubilizers and co-solvents are the most widely employed excipients in the formulation of parenterals. BASF offers a range of high-quality solubilization excipients and has unparalleled experience in quality and regulatory affairs, as well as solubility enhancement strategies.

Our excipients for parenterals are produced by qualified and experienced employees in line with the appropriate high-quality standards including documentation, equipment, utilities and personnel.



<https://pharma.basf.com/solutions/parenterals>



| Solution | Product | Functionality | Monograph title | FDA IID listing |
|------------|----------------------|--|--|-----------------|
| Excipients | Kolliphor® ELP | Non-ionic solubilizer and emulsifier (surfactant; HLB = 12–14) | Ph. Eur.: Macrogolglycerol ricinoleate; USP-NF: Polyoxyl 35 castor oil | Yes |
| | Kolliphor® HS 15 | Non-ionic solubilizer and emulsifier (surfactant; HLB = 15) | Ph. Eur.: Macrogol 15 hydroxystearate; USP-NF: Polyoxyl 15 hydroxystearate | Yes |
| | Kollidon® 12 PF | Solubilizer by complexation | Ph. Eur., USP-NF, JP: Povidone / Synthetic polymer | Yes |
| | Kollidon® 17 PF | Solubilizer by complexation | Ph. Eur., USP-NF, JP: Povidone / Synthetic polymer | Yes |
| | Kolliphor® P 188 Bio | Non-ionic block polymer solubilizer | Ph. Eur., USP-NF, JPE: Poloxamer 188; Polyoxyethylene (160) Polyoxypropylene (30) glycol | Yes |
| APIs | CN 600 TG | Omega-3-acid triglycerides, intended for parenteral nutrition | Ph. Eur | |



Solubilization

Poorly soluble drugs are one of the major challenges pharmaceutical manufacturers are facing. BASF offers a wide range of highly effective solubilization excipients and an unparalleled understanding of the corresponding process technologies. We are the leading partner in optimizing bioavailability and solubility of challenging APIs.





Our solutions enable you to achieve effective solubilization and bioavailability in various dosage forms – from solid dispersions to lipid-based drug delivery systems to soft gels. Moreover, we are a highly successful pioneer in the application of hot-melt extrusion technology in pharmaceutical production.



<https://pharma.basf.com/solutions/solubilization>








Solid dispersions

| Functionality | Product | Process | | | | Description | Monograph title*/Chemical name | |
|------------------------|--|----------------------|------------------|--------------|-----|--|--|--|
| | | Physical mixing | Melt granulation | Spray drying | HME | | | |
| Solubility enhancement | Soluplus® | ● | ● | ● | ● | Polymer designed for amorphous solid dispersions (ASDs), specifically to increase solubility and bioavailability of poorly water soluble drugs. Ideal for hot melt extrusion and spray drying. | Polyvinyl caprolactam – polyvinyl acetate – polyethylene glycol graft copolymer | |
| | Kolliphor® RH 40 | ● | ● | ● | ● | Non-ionic solubilizer. | Ph. Eur.: Macroglycerol hydroxystearate; USP-NF: Polyoxyl 40 hydrogenated castor oil | |
| | Kolliphor® HS 15 | ● | ● | ● | ● | Non-ionic solubilizer. | Ph. Eur.: Macrogol 15 hydroxystearate; USP-NF: Polyoxyl 15 hydroxystearate | |
| | Kolliphor® EL | ● | ● | ● | ● | Non-ionic solubilizer. | Ph. Eur.: Macroglycerol ricinoleate; USP-NF: Polyoxyl 35 castor oil; JPE: Polyoxyl 35 castor oil | |
| | Kolliphor® ELP | ● | ● | ● | ● | Purified Kolliphor® EL, especially for sensitive active ingredients. | Ph. Eur.: Macroglycerol ricinoleate USP-NF: Polyoxyl 35 castor oil | |
| | Kolliphor® SLS  | ● | ● | ● | ● | Ionic solubilizer and emulsifier. | Ph. Eur.: Sodium laurilsulfate; USP-NF, JP: Sodium lauryl sulfate | |
| | Kolliphor® P 188 Geismar | ● | ● | ● | ● | Polymeric solubilizer, emulsifier and plasticizer. | Ph. Eur., USP-NF: Poloxamer 188; JPE: Polyoxyethylene (160) polyoxypropylene (30) glycol | |
| | Kolliphor® P 338 Geismar | ● | ● | ● | ● | Polymeric solubilizer, emulsifier and plasticizer. | Ph. Eur., USP-NF: Poloxamer 338 | |
| | Kolliphor® P 407 Geismar | ● | ● | ● | ● | Polymeric solubilizer, emulsifier and plasticizer. | Ph. Eur., USP-NF: Poloxamer 407; JPE: Polyoxyethylene (196) polyoxypropylene (67) glycol | |
| | Kolliphor® PS 20  | ● | ● | ● | ● | Non-ionic solubilizer, emulsifier and co-emulsifier. | Ph. Eur., USP-NF: Polysorbate 20 | |
| | Kolliphor® PS 60  | ● | ● | ● | ● | Non-ionic solubilizer, emulsifier and co-emulsifier. | Ph. Eur., USP-NF, JPE: Polysorbate 60 | |
| | Kolliphor® PS 80  | ● | ● | ● | ● | Non-ionic solubilizer, emulsifier and co-emulsifier. | Ph. Eur., USP-NF: Polysorbate 80 | |
| | Kollidon® 12 PF Kollidon® 17 PF | P P | ● | ● | ● | ● | Endotoxin controlled – low molecular weight povidone for solubilization, stabilization and crystallization inhibition. | Ph. Eur., USP-NF, JP: Povidone |
| | Kollidon® 25 Kollidon® 30 ^A | P P | ● | | ● | ● | Medium-molecular weight Povidone for solubilization, dispersion and oral liquid and oral semi-solid formulations crystallization inhibition. | Ph. Eur., USP-NF, JP: Povidone |
| | Kollidon® 90 Evo | P | ● | | ● | ● | High-molecular weight Povidone for solubilization, dispersion and crystallization inhibition. | Ph. Eur., USP-NF, JP: Povidone |
| | Kollisol® PEG 1000 | | ● | ● | | ● | Semi-solid polyethylene glycols. | Ph. Eur.: Macrogols; USP-NF: Polyethylene Glycol |
| | Kollisol® PEG 1450 | | ● | ● | | ● | Semi-solid polyethylene glycols. | USP-NF: Polyethylene Glycol |
| | Kollisol® PEG 8000 | | ● | ● | | ● | Semi-solid polyethylene glycols. | Ph. Eur.: Macrogols; USP-NF: Polyethylene Glycol |


Solid dispersions

| Functionality | Product | Process | | | | Description | Monograph title*/Chemical name | |
|---------------|------------------------------------|----------------------|------------------|--------------|-----|---|--|--|
| | | Physical mixing | Melt granulation | Spray drying | HME | | | |
| Matrices | Soluplus® | ● | ● | ● | ● | Polymer designed for amorphous solid dispersions (ASDs), specifically to increase solubility and bioavailability of poorly water soluble drugs. Ideal for hot melt extrusion and spray drying. | Polyvinyl caprolactam – polyvinyl acetate – polyethylene glycol graft copolymer | |
| | Kollidon® VA 64 | | ● | ● | ● | Copolymer designed for creation of amorphous solid dispersions (ASDs) – instant release matrix, solubilizer, crystallization inhibitor. Soluble in organic solvents; high acceptability in solid oral doses. Ideal and commonly used in HME and spray drying. | Ph. Eur., USP-NF: Copovidone; JPE: Copolyvidone | |
| | Kollidon® SR | | ● | ● | ● | Controlled release matrix. May be blended with water soluble polymers to tailor release. | 80% Polyvinyl acetate and 19% povidone, 0.8% lauryl sulfate and 0.2% silica | |
| | Kollidon® 12 PF Kollidon® 17 PF | P P | | ● | ● | ● | Endotoxin controlled – low molecular weight povidone for solubilization, stabilization and crystallization inhibition. | Ph. Eur., USP-NF, JP: Povidone |
| | Kollidon® 25 | P | | ● | ● | ● | For instant release matrices including solubilization and crystallization inhibition. | Ph. Eur., USP-NF, JP: Povidone |
| | Kollidon® 30 ^Δ | P | | | ● | | For instant release matrices including solubilization and crystallization inhibition. Suitable for spray drying. | Ph. Eur., USP-NF, JP: Povidone |
| | Kollicoat® MAE 100-55 | | ● | ● | ● | ● | Non-neutralized, weakly acidic copolymer that dissolves at a pH above 5.5. Dust free powder grade. | Ph. Eur.: Methacrylic acid – ethyl acrylate copolymer (1:1) type A; USP-NF: Methacrylic acid and ethyl acrylate copolymer; JPE: Dried methacrylic copolymer LD |
| | Kollicoat® MAE 100 P | | ● | ● | ● | ● | Partially neutralized, weakly acidic copolymer that dissolves at a pH above 5.5. | Ph. Eur.: Methacrylic acid – ethyl acrylate copolymer (1:1), type B; USP-NF: Partially-neutralized methacrylic acid and ethyl acrylate copolymer |





Solutions

| Functionality | Product | Description | Monograph title*/Chemical name |
|------------------------------|--|--|---|
| Solubilizers and surfactants | Soluplus® | Polymer specifically designed to increase solubility and bioavailability of poorly soluble drugs. | Polyvinyl caprolactam – polyvinyl acetate – polyethylene glycol graft copolymer |
| | Kolliphor® RH 40 | Non-ionic solubilizer and emulsifier. | Ph. Eur.: Macrogolglycerol hydroxystearate; USP-NF: Polyoxyl 40 hydrogenated castor oil |
| | Kolliphor® HS 15 | Non-ionic solubilizer and emulsifier. Particularly suitable for parenteral applications. | Ph. Eur.: Macrogol 15 hydroxystearate; USP-NF: Polyoxyl 15 hydroxystearate |
| | Kolliphor® EL | Non-ionic solubilizer and emulsifier. | Ph. Eur.: Macrogolglycerol ricinoleate; USP-NF: Polyoxyl 35 castor oil |
| | Kolliphor® ELP | Purified Kolliphor® EL, especially for sensitive active ingredients to improve their stability. Particularly suitable for parenteral applications. | Ph. Eur.: Macrogolglycerol ricinoleate; USP-NF: Polyoxyl 35 castor oil |
| | Kolliphor® SML 20  | Non-ionic solubilizer and emulsifier for pharmaceutical applications. | Ph. Eur.: Sorbitan Laurate |
| | Kolliphor® SLS  | Ionic solubilizer and emulsifier. | Ph. Eur.: Sodium laurilsulfate; USP-NF, JP: Sodium lauryl sulfate |
| | Kolliphor® P 188 Geismar | Polymeric solubilizer, emulsifier and plasticizer. | Ph. Eur., USP-NF, JP: Poloxamer 188; JPE: Polyoxyethylene (160) polyoxypropylene (30) glycol |
| | Kolliphor® P 338 Geismar | Polymeric solubilizer, emulsifier and plasticizer. | Ph. Eur., USP-NF, JPE: Poloxamer 338 |
| | Kolliphor® P 407 Geismar | Polymeric solubilizer, emulsifier and plasticizer. | Ph. Eur., USP-NF, JPE: Poloxamer 407; JPE: Polyoxyethylene (196) polyoxypropylene (67) glycol |
| | Kolliphor® PS 20  | Non-ionic solubilizer, emulsifier, co-emulsifier and plasticizer. | Ph. Eur., USP-NF: Polysorbate 20 |
| | Kolliphor® PS 60  | Non-ionic solubilizer, emulsifier, co-emulsifier and plasticizer. | Ph. Eur., USP-NF, JPE: Polysorbate 60 |
| | Kolliphor® PS 80  | Non-ionic solubilizer, emulsifier, co-emulsifier and plasticizer. | Ph. Eur., USP-NF, JPE: Polysorbate 80 |
| Crystallization inhibitor | Kollidon® 12 PF Kollidon® 17 PF | P Low-molecular weight povidone that is endotoxin controlled. Crystallization inhibitor and stabilizer in injectables and ophthalmic products. | Ph. Eur., USP-NF, JP: Povidone |
| | Kollidon® 25 Kollidon® 30 ^A | P Medium-molecular weight povidone used as a solubilizing agent, dispersant and crystallization inhibitor. | Ph. Eur., USP-NF, JP: Povidone |
| | Kollidon® 90 F | P High-molecular weight povidone used as a solubilizing agent, dispersant and crystallization inhibitor. | Ph. Eur., USP-NF, JP: Povidone |
| | Kollidon® VA 64 | Copolymer designed for creation of amorphous solid dispersions (ASDs) – instant release matrix, solubilizer, crystallization inhibitor. High solubility in organic solvents, high acceptability in solid oral doses. | Ph. Eur., USP-NF: Copovidone; JEP: Copolyvidone |
| | Soluplus® | Solubilizing agent, crystallization inhibitor, stabilizer. | Polyvinyl caprolactam – polyvinyl acetate – polyethylene glycol graft copolymer |


Solutions

| Functionality | Product | Description | Monograph title*/Chemical name |
|---------------------|--|---|--|
| Solvents | Kollisol [®] PG | Solvent for oral and topical applications. | Ph. Eur., USP-NF, JP, FCC: Propylene glycol |
| | Kollisol [®] PEG 300 | Solvent for oral and topical applications. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol, JPE: Macrogol 300; FCC: Polyethylene glycols |
| | Kollisol [®] PEG 300 G | Solvent for oral and topical applications. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol |
| | Kollisol [®] PEG 400 | Solvent for oral and topical applications. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol; JP: Macrogol 400; FCC: Polyethylene glycols |
| | Kollisol [®] PEG 400 G | Solvent for oral and topical applications. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol |
| | Kollisol [®] P 124 Geismar | Solvent for APIs, dispersing agent for liquid dispersions, stabilizer and co-emulsifier in semi-solid formulations. | Ph. Eur., USP-NF, JPE: Polyoxyethylene (20) polyoxypropylene (20) glycol |
| | Kollisol [®] GTA | Commonly used, both semi-hydrophilic and semi-hydrophobic solvent. | Ph. Eur., USP-NF: Triacetin |
| | Kollisol [®] PYR | Solvent for injectables and oral formulations for animal health. | Ph. Eur.: Pyrrolidone |
| | Kollisol [®] MCT 70  | Solubilizer for lipophilic drugs. | Ph. Eur.: Triglycerides, medium-chain, USP-NF: Medium-chain triglycerides |
| Viscosity enhancers | Kollidon [®] 90 Evo P | Enhances viscosity. Soluble in water and many organic solvents. | Ph. Eur., USP-NF, JP: Povidone |
| | Kolliphor [®] P 407 Geismar | Enhances viscosity. Thermoreversible gelling effect. | Ph. Eur., USP-NF, Poloxamer 407; JPE: Polyoxyethylene (196) polyoxypropylene (67) glycol |
| Gel formers | Kolliphor [®] P 407 Geismar | Enhances viscosity. Thermoreversible gelling effect. | Ph. Eur., USP-NF, Poloxamer 407; JPE: Polyoxyethylene (196) polyoxypropylene (67) glycol |
| | Kolliphor [®] P 338 Geismar | Enhances viscosity. Thermoreversible gelling effect. | Ph. Eur., USP-NF, Poloxamer 338 |
| | Kolliphor [®] P 188 Geismar | Enhances viscosity. Thermoreversible gelling effect. | Ph. Eur., USP-NF, Poloxamer 188; JPE: Polyoxyethylene (160) polyoxypropylene (30) glycol |

Emulsions

| Functionality | Product | Description | Monograph title*/Chemical name |
|------------------------------|---|---|---|
| Emulsifiers/ Solubilizers | Kolliphor® RH 40 | Non-ionic solubilizer. High acceptability in SEDDS formulations. | Ph. Eur.: Macrogolglycerol hydroxystearate; USP-NF: Polyoxyl 40 hydrogenated castor oil |
| | Kolliphor® HS 15 | Non-ionic solubilizer in paste form used in combination with a matrix polymer. | Ph. Eur.: Macrogol 15 hydroxystearate; USP-NF: Polyoxyl 15 hydroxystearate |
| | Kolliphor® EL | Non-ionic solubilizer. High acceptability in SEDDS formulations. | Ph. Eur.: Macrogolglycerol ricinoleate; USP-NF: Polyoxyl 35 castor oil; polyoxyl 35 castor oil |
| | Kolliphor® ELP | Purified Kolliphor® EL, especially for sensitive active ingredients to improve their stability. | Ph. Eur.: Macrogolglycerol ricinoleate; USP-NF: Polyoxyl 35 castor oil |
| | Kolliphor® SML 20  | Non-ionic solubilizer and emulsifier for pharmaceutical applications. | Ph. Eur.: Sorbitan Laurate |
| | Kolliphor® SLS  | Ionic solubilizer and emulsifier. | Ph. Eur.: Sodium laurilsulfate; USP-NF, JP: Sodium lauryl sulfate |
| | Kolliphor® P 188 Geismar | Polymeric solubilizer, emulsifier and plasticizer. | Ph. Eur., USP-NF, JP: Poloxamer 188; JPE: Polyoxyethylene (160) polyoxypropylene (30) glycol |
| | Kolliphor® P 338 Geismar | Polymeric solubilizer, emulsifier and plasticizer. | Ph. Eur., USP-NF, Poloxamer 338 |
| | Kolliphor® P 407 Geismar | Polymeric solubilizer, emulsifier and plasticizer. | Ph. Eur., USP-NF, Poloxamer 407; JPE: Polyoxyethylene (196) polyoxypropylene (67) glycol |
| | Kolliphor® PS 20  | Non-ionic solubilizer, emulsifier and co-emulsifier. | Ph. Eur., USP-NF: Polysorbate 20 |
| | Kolliphor® PS 60 | Non-ionic solubilizer, emulsifier and co-emulsifier. | Ph. Eur., USP-NF, JPE: Polysorbate 60 |
| | Kolliphor® PS 80  | Non-ionic solubilizer, emulsifier and co-emulsifier. | Ph. Eur., USP-NF, JPE: Polysorbate 80 |
| | Kollisolv® P 124 Geismar | High acceptability in SEDDS formulations. | Ph. Eur., USP-NF: Poloxamer 124; JPE: Polyoxyethylene (20) polyoxypropylene (20) glycol |


Emulsions

| Functionality | Product | Description | Monograph title*/Chemical name |
|---------------|---|---|--|
| Solvents | Kollisolv® PG | Solvent for oral and topical applications. | Ph. Eur., USP-NF, JP, FCC: Propylene glycol |
| | Kollisolv® PEG 300 | Solvent for oral and topical applications. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol; JPE: Macrogol 300; FCC: Polyethylene glycols |
| | Kollisolv® PEG 300 G | Solvent for oral and topical applications. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol |
| | Kollisolv® PEG 400 | Solvent for oral and topical applications. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol; JP: Macrogol 400; FCC: Polyethylene glycols |
| | Kollisolv® PEG 400 G | Solvent for oral and topical applications. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol |
| | Kollisolv® P 124 Geismar | Solvent for APIs, dispersing agent for liquid dispersions, stabilizer and co-emulsifier in semi-solid formulations. | Ph. Eur., USP-NF: Poloxamer 124; JPE: Polyoxyethylene (20) polyoxypropylene (20) glycol |
| | Kollisolv® GTA | Commonly used, both semi-hydrophilic and semi-hydrophobic solvent. | Triacetin |
| | Kollisolv® PYR | Solvent for injectables and oral formulations for animal health. | Ph. Eur.: Pyrrolidone |
| Lipids | Kollisolv® MCT 70  | Solubilizer for lipophilic drugs. | Ph. Eur.: Triglycerides, medium-chain, USP-NF: Medium-chain triglycerides |
| Co-solvents | Kollisolv® PEG 300 | Solvent for oral and topical applications. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol, JPE: Macrogol 300; FCC: Polyethylene glycols |
| | Kollisolv® PEG 300 G | Solvent for oral and topical applications. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol |
| | Kollisolv® PEG 400 | Solvent for oral and topical applications. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol; JP: Macrogol 400; FCC: Polyethylene glycols |
| | Kollisolv® PEG 400 G | Solvent for oral and topical applications. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol |
| | Kollisolv® P 124 Geismar | Solvent for APIs, dispersing agent for liquid dispersions, stabilizer and co-emulsifier in semi-solid formulations. | Ph. Eur., USP-NF, JPE: Polyoxyethylene (20) polyoxypropylene (20) glycol |
| | Kollisolv® GTA | Commonly used solvent. | Triacetin |
| | Kollisolv® PYR | Solvent for injectables and oral formulations for animal health. | Ph. Eur.: Pyrrolidone |

Suspensions










| Functionality | Product | Process | | | Description | Monograph title*/Chemical name |
|----------------------------|------------------------------------|--|---------------------|--------------|--|--|
| | | Physical mixing, e.g. wet granulation | Melt granulation | Spray drying | | |
| Reduction of sedimentation | Kollidon® CL-M | | ● | | Reduces sedimentation by steric effects. Insoluble. | Ph. Eur., USP-NF, JP: Crospovidone type B |
| | Kolliphor® P 407 Geismar | ● | ● | ● | Thickening agent and gel former, as a co-emulsifier and viscosity enhancer in creams and liquid emulsions. Also stabilizes topically and orally administered suspensions and is used in tooth-pastes, gargles and mouthwashes. Used in sustained release formulations. | Ph. Eur., USP-NF, Poloxamer 407; JPE: Polyoxyethylene (196) polyoxypropylene (67) glycol |
| | Kollidon® 90 Evo | P | ● | ● | Reduces sedimentation by viscosity enhancement. Soluble in water and many organic solvents. | Ph. Eur., USP-NF, JP: Povidone |
| Redispersing agent | Kollidon® CL-M | | ● | | Sedimentation inhibitor in suspensions. | Ph. Eur., USP-NF, JP: Crospovidone type B |
| | Kollidon® 90 Evo | P | ● | ● | Reduces sedimentation by viscosity enhancement. Soluble in water and many organic solvents. | Ph. Eur., USP-NF, JP: Povidone |
| | Kolliphor® HS 15 | | ● | ● | Non-ionic solubilizer in paste form used in combination with a matrix polymer. | Ph. Eur.: Macrogol 15 hydroxystearate; USP-NF: Polyoxyl 15 hydroxystearate |
| | Kollidon® 12 PF Kollidon® 17 PF | P P | ● | ● | Low-molecular weight povidone that is endotoxin controlled. Crystallization inhibitor and stabilizer in injectables and ophthalmic products. | Ph. Eur., USP/NF, JP: Povidone |
| | Kollidon® 12 PF Kollidon® 17 PF | P P | ● | ● | Low-molecular weight povidone that is endotoxin controlled. Crystallization inhibitor and stabilizer in injectables and ophthalmic products. | Ph. Eur., USP-NF, JP: Povidone |

Softgel and capsule fills

| Functionality | Product | Description | Monograph title*/Chemical name |
|----------------------------|---|---|--|
| Solvents and fills | Kollisolv® MCT 70 |  Oil fill for solubilization of lipophilic APIs. | Ph. Eur.: Triglycerides, medium-chain, USP-NF: Medium chain triglycerides |
| | Kollisolv® PEG 300 | Hydrophilic fill for solubilization of hydrophilic APIs. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol, JPE: Macrogol 300; FCC: Polyethylene glycols |
| | Kollisolv® PEG 300 G | Hydrophilic fill for solubilization of hydrophilic APIs. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol |
| | Kollisolv® PEG 400 | Hydrophilic fill for solubilization of hydrophilic APIs. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol; JP: Macrogol 400; FCC: Polyethylene glycols |
| | Kollisolv® PEG 400 G | Hydrophilic fill for solubilization of hydrophilic APIs. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol |
| | Kollisolv® PEG 600 | Hydrophilic fill for solubilization of hydrophilic APIs. | Ph. Eur.: Macrogols; USP-NF: Polyethylene glycol |
| | Kollisolv® PEG 400 LA | Hydrophilic fill for solubilization of hydrophilic APIs. Low aldehyde content to prevent gelatin crosslinking. | USP-NF: Polyethylene glycol; JP: Macrogol 400 |
| | Kollisolv® PEG 600 LA | Hydrophilic fill for solubilization of hydrophilic APIs. Low aldehyde content to prevent gelatin crosslinking. | USP-NF: Polyethylene glycol; JP: Macrogol 600 |
| | Kollisolv® PG | Versatile hydrophilic solvent. | Ph. Eur., USP-NF, JP, FCC: Propylene glycol |
| Kollisolv® P 124 Geismar | Liquid amphiphilic polymer for solubilizing APIs. | Ph. Eur., USP-NF: Poloxamer 124; JPE: Polyoxyethylene (20) polyoxypropylene (20) glycol | |
| Crystallization inhibition | Kollidon® 12 PF Kollidon® 17 PF | P Endotoxin controlled, low-molecular weight povidone. Solubilizing agent and crystallization inhibitor. | Ph. Eur., USP-NF, JP: Povidone |
| | Kollidon® 30 ^Δ | P Low-molecular weight povidone. Solubilizing agent and crystallization inhibitor. | Ph. Eur., USP-NF, JP: Povidone |
| | Kollidon® 90 Evo | P Soluble povidone, viscosity enhancer. | Ph. Eur., USP-NF, JP: Povidone |
| | Kollidon® VA 64 | Solubilizing agent, dispersant and crystallization inhibitor. | Ph. Eur., USP-NF: Copovidone; JPE: Copolyvidone |
| | Soluplus® | Polymer specifically designed to increase solubility and bioavailability of poorly soluble drugs. | Polyvinyl caprolactam – polyvinyl acetate – polyethylene glycol graft copolymer |



Softgel and capsule fills

| Functionality | Product | Description | Monograph title*/Chemical name |
|---|-----------------------------|---|---|
| Solubility enhancement and emulsification | Kolliphor® CS 12 |  Non-ionic emulsifiers and solubilizers. | Ph. Eur.: Macrogol cetostearyl ether 12 |
| | Kolliphor® CS 20 |  Non-ionic emulsifiers and solubilizers. | Ph. Eur.: Macrogol cetostearyl ether 20, USP-NF: Polyoxyl 20 cetostearyl ether |
| | Kolliphor® EL | Non-ionic O-W emulsifier and solubilizer. | Ph. Eur.: Macrogolglycerol ricinoleate; USP-NF: Polyoxyl 35 castor oil; JPE: Polyoxyl 35 castor oil |
| | Kolliphor® ELP | Purified Kolliphor® EL, especially for sensitive active pharmaceutical ingredients. | Ph. Eur.: Macrogolglycerol ricinoleate; USP-NF: Polyoxyl 35 castor oil |
| | Kolliphor® RH 40 | Non-ionic O-W emulsifier and solubilizer. | Ph. Eur.: Macrogolglycerol hydroxystearate, USP-NF: Polyoxyl 40 hydrogenated castor oil |
| | Kolliphor® HS 15 | Non-ionic O-W emulsifier and solubilizer. | Ph. Eur.: Macrogol 15 hydroxystearate, USP-NF: Polyoxyl 15 hydroxystearate |
| | Kolliphor® PS 20 |  Non-ionic O-W emulsifier and solubilizer. | Ph. Eur., USP-NF: Polysorbate 20 |
| | Kolliphor® PS 60 |  Non-ionic O-W emulsifier and solubilizer. | Ph. Eur., USP-NF, JPE: Polysorbate 60 |
| | Kolliphor® PS 80 |  Non-ionic O-W emulsifier and solubilizer. | Ph. Eur., USP-NF, JPE: Polysorbate 80 |
| | Kollisoliv® P 124 Geismar | Liquid amphiphilic polymer, solubilizer. | Ph. Eur., USP-NF: Poloxamer 124; JPE: Polyoxyethylene (20) polyoxypropylene (20) glycol |
| | Kolliphor® P 188 Geismar | Solid amphiphilic polymer, solubilizer. | Ph. Eur., USP-NF: Poloxamer 188; JPE: Polyoxyethylene (160) polyoxypropylene (30) glycol |
| | Kolliphor® P 338 Geismar | Solid amphiphilic polymer, solubilizer. | Ph. Eur., USP-NF: Poloxamer 338 |
| | Kolliphor® P 407 Geismar | Solid amphiphilic polymer, solubilizer. | Ph. Eur., USP-NF, JPE, Poloxamer 407, Polyoxyethylene (196) polyoxypropylene (67) glycol |
| | Kolliwax® GMS II |  Co-emulsifier and viscosity enhancer. | Ph. Eur.: Glycerol monostearate 40-55 (type II); USP-NF: Mono- and di-glycerides |
| | Kolliwax® CSA 50 |  Co-emulsifier and viscosity enhancer. | Ph. Eur., USP-NF, JPE: Cetostearyl alcohol |
| | Kolliwax® HCO | Lipid matrix. | Ph. Eur.: Castor oil hydrogenated; USP-NF: Hydrogenated castor oil; JP: Hydrogenated oil |
| | Kolliwax® S |  Emulsifying and solubilizing agent, viscosity enhancer. | Ph. Eur., USP-NF, JP: Stearic acid 50 |
| | Novata® B PH, BC PH, BCF PH |  Lipidic matrix and viscosity enhancer. | Ph. Eur.: Hard fat |

Biopharma Ingredients

With over 50 years of experience in EO/PO chemistry, BASF Pharma Solutions, the leading supplier of poloxamer 188, is pleased to introduce Kolliphor® P 188 Bio – specifically designed to meet the stringent requirements of biologics manufacturers for purity, consistency and performance in mammalian cell culture systems.

In these cell culture systems, live cells are kept in suspension within the medium in bioreactors and are subject to some degree of physical (shear) stress in the process.



<https://pharma.basf.com/solutions/biopharma>



High purity poloxamer designed for biologics manufacturing

BASF is the leading manufacturer of poloxamer 188 (Kolliphor® P 188). In bioprocessing, poloxamer 188 has been extensively researched and has been found to be the most effective ingredient to provide shear protection in mammalian cell cultures.

BASF is committed to provide Kolliphor® P 188 Bio, which is designed to meet your needs in quality, consistency, and performance in cell culture systems during the manufacturing of biologic drugs including monoclonal antibodies and advanced therapies.

Kolliphor® P 188 Bio is a premium, fit-for-purpose product designed to minimize risk in cell culture manufacturing. It is used as an additive to the cell culture medium to reduce the shear stress, which improves cell viability and the resulting biologic drug yield. The purity of the product is critical, and requires special attention to assure every lot produced is suitable for use with cell cultures. Moreover, Kolliphor® P 188 Bio will allow customers to reduce the supply chain complexity and minimizes the need for additional testing.

Kolliphor® P 188 Bio

- Consistent performance lowers manufacturing risk
- Validated RP-HPLC assay to ensure highest purity
- Enhanced packaging
- Compendial grade with Drug Master File

Kolliphor® P 188 Cell Culture

- Consistent performance lowers manufacturing risk
- Validated RP-HPLC assay to ensure highest purity
- Enhanced packaging
- Compendial grade with Drug Master File

| Product | Description | Monograph title*/Chemical name |
|-------------------------------|--|---|
| Kolliphor® P 188 Bio | For use as a shear protectant in cell culture manufacturing processes. | Ph. Eur., USP-NF: Poloxamer 188; JPE: Polyoxyethylene (160), Polyoxypropylene (30) glycol |
| Kolliphor® P 188 Cell Culture | Next generation poloxamer for shear protection. | Ph. Eur., USP-NF: Poloxamer 188; JPE: Polyoxyethylene (160), Polyoxypropylene (30) glycol |

*The product meets the test requirements of the current monograph of "Polyoxyethylene (160) Polyoxypropylene (30) Glycol" JPE, containing BHT

Surfactants for biologic formulations

Biologic formulations require excipients of highest quality standards as they directly bypass the body's natural defenses. Our surfactants for biologic formulations are produced in Ludwigshafen, Germany and Geismar, LA, USA by qualified and experienced personnel in line with IPEC-PQG GMP standards, and also subject to microbiological and endotoxin testing prior to release. In addition, our technical experts have access to industry-leading tools and analytics, coupled with a deep and profound understanding of our excipients, which allows us to enable our customers to tackle their formulation challenges rapidly and efficiently.

| Product | Functionality | Monograph title*/Chemical name | FDA IID listing |
|------------------------------|------------------------------------|--|-----------------|
| Kolliphor® P188 Bio | Non-ionic surfactant (HLB = 29) | Ph. Eur., USP, JPE: Poloxamer 188 | Yes |
| Kolliphor® P188 Cell Culture | Non-ionic surfactant (HLB = 29) | Ph. Eur., USP, JPE: Poloxamer 188 | Yes |
| Kollipro™ Urea Granules | Processing aid | Ph. Eur., USP: Urea (carbamide) | No |
| Soluplus® | Processing aid | N/A: Polyvinyl caprolactam – polyvinyl acetate – polyethylene glycol graft Copolymer | No |
| Kolliphor® SLS | Anionic emulsifier | Ph.Eur.: Sodium laurilsulfate; USP/NF, JP: Sodium lauryl sulfate | No |
| Kolliphor® HS 15 | Non-ionic surfactant (HLB = 15) | Ph. Eur.: Macrogol 15 Hydroxystearate USP: Polyoxyl 15 Hydroxystearate | Yes |
| Kolliphor® ELP | Non-ionic surfactant (HLB = 12-14) | Ph. Eur.: Macrogolglycerol ricinoleate USP: Polyoxyl 35 castor oil | Yes |





APIs

For over 75 years, BASF has been driving excellence in active pharmaceutical ingredients (APIs). Backed by this wealth of experience, we offer a proven portfolio of products that delivers consistent safety and reliability.

What's more, we have achieved worldwide leadership in generic actives such as ibuprofen and omega-3. With a strong international presence, BASF is a truly global partner that can also offer reliable local support. And thanks to our state-of-the-art production facilities located around the world, we can deliver the products you need – wherever and whenever you need them.



<https://pharma.basf.com/solutions/apis>



| Product | CAS no. | Registration | | | | Comments | Description |
|----------------------------|------------|--------------|------|------|--------|-----------------------|---|
| | | CEP | ASMF | JDMF | US-DMF | | |
| Ibuprofen | | | | | | | |
| Ibuprofen 25 | 15687-27-1 | ● | ● | ● | ● | USP, Ph. Eur., JP, IP | Particle size: D (0.5) = 20–33 µm. |
| Ibuprofen 38 | 15687-27-1 | ● | ● | ● | ● | USP, Ph. Eur., JP, IP | Particle size: D (0.5) = 33–45 µm. |
| Ibuprofen 50 | 15687-27-1 | ● | ● | ● | ● | USP, Ph. Eur., JP, IP | Particle size: D (0.5) = 45–60 µm. |
| Ibuprofen 70 | 15687-27-1 | ● | ● | ● | ● | USP, Ph. Eur., JP, IP | Particle size: D (0.5) = 60–85 µm. |
| Ibuprofen DC 85 W | 15687-27-1 | | ● | | ● | | Direct compressible Ibuprofen with 85% drug content. |
| Ibuprofen sodium dihydrate | 31121-93-4 | | ● | | ● | | Fast-acting Ibuprofen. |
| Other | | | | | | | |
| PVP-Iodine 30/06 | 25655-41-8 | ● | ● | ● | ● | USP, Ph. Eur., JP, IP | Oral laxative which acts by osmotic retention of water in the intestine. PEG 3350 is applicable for long-term therapy because it has no effect on the cardiovascular system, causes no irritation of the intestinal mucosa. |
| Dexpanthenol Ph. Eur. | 81-13-0 | ● | ● | | | USP, Ph. Eur. | Dermaticum, treatment of wounds, promotion of epithelization. |
| L-menthol pharma | 2216-51-5 | ● | ● | | ● | USP, Ph. Eur., JP | Antitussive, nasal decongestant, antihistamine, expectorant, throat irritation relief, topical analgesic, local anesthetic. Available as L-menthol flakes. |



| Product | CAS no. | Registration | | | | | Comments | Description |
|-----------------------------------|-------------------|--------------|------|------|--------|--------|-----------------------|---|
| | | CEP | ASMF | JDMF | CN-DMF | US-DMF | | |
| Omega-3 Pharma API's | | | | | | | | |
| Maxomega® EPA 96 EE | 86227-47-6 | | | | ● | ● | IN-DMF | Highly concentrated and purified EPA marine omega-3 oil. Classified as a lipid-modifying agent. Used to reduce triglyceride levels. |
| Maxomega® EPA 97 EE | 86227-47-6 | | | ● | | | JP | |
| Maxomega® DHA 95 EE AS | DHA EE 81926-94-5 | | | | | | US DMF in preparation | Docosahexanoic acid ethylester, algal based, no drug product approved so far. |
| Omega-3-acid ethyl esters (K85EE) | EPA EE 86227-47-6 | ● | | ● | ● | ● | USP, Ph. Eur., KR-DMF | Highly concentrated and purified EPA/DHA marine omega-3 oil. Classified as a lipid-modifying agent. Used to reduce triglyceride levels. |
| | DHA EE 81926-94-5 | | | | | | | |
| CN 600 TG | 10417-94-4 (EPA) | ● | | | | | Ph. Eur. | Omega-3-acid triglycerides. Intended for parenteral nutrition. |
| | 6217-54-5 (DHA) | | | | ● | | | |

Further omega-3 products might be available on special request only

| Product | CAS no. | EPA (min.) | DHA (min.) | EPA + DHA (min.) | Description |
|--------------------------|-------------------------------------|------------|------------|------------------|--|
| Omega-3 Nutrition | | | | | |
| PronovaPure® 46:38 EE | EPA EE 86227-47-6/DHA EE 81926-94-5 | 430 mg/g | 347 mg/g | 800 mg/g | Highly concentrated and purified marine omega-3 oil. |
| PronovaPure® 500:200 EE | EPA EE 86227-47-6/DHA EE 81926-94-5 | 500 mg/g | 200 mg/g | 700 mg/g | Highly concentrated and purified marine omega-3 oil. |
| PronovaPure® 460:180 EE | EPA EE 86227-47-6/DHA EE 81926-94-5 | 460 mg/g | 180 mg/g | 640 mg/g | Highly concentrated and purified marine omega-3 oil. |
| PronovaPure® 400:200 EE | EPA EE 86227-47-6/DHA EE 81926-94-5 | 400 mg/g | 200 mg/g | 600 mg/g | Highly concentrated and purified marine omega-3 oil. |
| PronovaPure® 360:240 EE | EPA EE 86227-47-6/DHA EE 81926-94-5 | 360 mg/g | 240 mg/g | 600 mg/g | Highly concentrated and purified marine omega-3 oil. |
| PronovaPure® 150:500 EE | EPA EE 86227-47-6/DHA EE 81926-94-5 | 150 mg/g | 500 mg/g | 650 mg/g | Highly concentrated and purified marine omega-3 oil. |
| PronovaPure® 500:200 TG | EPA 10417-94-4/DHA 6217-54-5 | 500 mg/g | 200 mg/g | 700 mg/g | Highly concentrated and purified marine omega-3 oil. |
| PronovaPure® 400:200 TG | EPA 10417-94-4/DHA 6217-54-5 | 400 mg/g | 200 mg/g | 600 mg/g | Highly concentrated and purified marine omega-3 oil. |
| PronovaPure® 360:240 TG | EPA 10417-94-4/DHA 6217-54-5 | 360 mg/g | 240 mg/g | 600 mg/g | Highly concentrated and purified marine omega-3 oil. |
| PronovaPure® 150:500 TG | EPA 10417-94-4/DHA 6217-54-5 | 150 mg/g | 500 mg/g | 650 mg/g | Highly concentrated and purified marine omega-3 oil. |

PronovaPure® is to be used in dietary supplement applications only





Pharma Solutions Product Overview by Chemistry

Excipients

| Chemistry | USP-NF | Ph. Eur. | JP/JPE | Not monographed/ Co-processed excipients | BASF brand name | Page |
|---|---|--|---|---|--|----------------------------|
| Cetostearyl alcohol | Cetostearyl alcohol | Cetostearyl alcohol | Cetostearyl alcohol | | Kolliwax® CSA 50, 70 | 18, 21, 33 |
| Cetostearyl alcohol (type A), emulsifying | | Cetostearyl alcohol (type A), emulsifying | | | Kolliphor® CS A | 17, 18 |
| Cetyl alcohol | Cetyl alcohol | Cetyl alcohol | | | Kolliwax® CA | 18, 21 |
| Cetyl palmitate 15 | | Cetyl palmitate 15 | | | Kollicream® CP 15 | 15 |
| Coco-caprylate-caprate | Cocoyl carylocaprate | Cocoyl caprylocaprate | | | Kollicream® 3 C | 15 |
| Copovidone | Copovidone | Copovidone | Copovidone | | Kollidon® VA 64, VA 64 Fine | 07, 13, 19, 20, 26, 27, 32 |
| Crospovidone | Crospovidone | Crospovidone | Crospovidone | | Kollidon® CL, CL-F, CL-SF, CL-M | 07, 20, 21, 31 |
| Decyl oleate | | Decyl oleate | | | Kollicream® DO | 15 |
| Ethylene glycol and vinyl alcohol graft copolymer | Ethylene glycol and vinyl alcohol graft copolymer | Macrogol poly(vinyl alcohol) grafted copolymer | Polyvinyl alcohol-polyethylene glycol graft copolymer | | Kollicoat® IR | 07, 10, 19 |
| Excipient based on Kollicoat® IR and monographed raw materials | | | | Excipient based on Kollicoat® IR and monographed raw materials | Kollicoat® Protect | 10 |
| Hard fat | | Hard fat | | | Novata® B PH, BC PH, BCF PH | 21, 33 |
| Hydrogenated castor oil | Hydrogenated castor oil | Castor oil, hydrogenated | Hydrogenated oil | | Kolliwax® HCO | 09, 10, 13, 18, 33 |
| Isopropyl myristate | Isopropyl myristate | Isopropyl myristate | | | Kollicream® IPM | 15, 20, 21 |
| Macrogol cetostearyl ether 12 | | Macrogol cetostearyl ether 12 | | | Kolliphor® CS 12 | 16, 33 |
| Medium-chain triglycerides | Medium-chain triglycerides | Triglycerides, medium-chain | | | Kollisol® MCT 70 | 13, 16, 21, 28, 30, 32 |
| Methacrylic acid and ethyl acrylate copolymer NF | Methacrylic acid and ethyl acrylate copolymer | Methacrylic acid – ethyl acrylate copolymer (1:1) type A | Dried methacrylic acid copolymer LD | | Kollicoat® MAE 100-55, MAE 100-55 Fine | 11, 26 |
| Methacrylic acid copolymer dispersion | Methacrylic acid copolymer dispersion | Methacrylic acid – ethyl acrylate copolymer (1:1) dispersion 30% | Methacrylic acid copolymer LD | | Kollicoat® MAE 30 DP | 11 |
| Methyl-methacrylate – diethylaminoethyl methacrylate co-polymer | | | | Methyl-methacrylate – diethylaminoethyl methacrylate co-polymer | Kollicoat® Smartseal 100 P | 10, 12 |
| Methyl-methacrylate – diethylaminoethyl methacrylate co-polymer | | | | Methyl-methacrylate – diethylaminoethyl methacrylate co-polymer | Kollicoat® Smartseal 30 D | 10, 12 |

Excipients

| Chemistry | USP-NF | Ph. Eur. | JP/JPE | Not monographed/ Co-processed excipients | BASF brand name | Page |
|--|---|---|--|--|---|--|
| Mixture of cetyl stearyl alcohol, sodium lauryl sulfate and sodium cetyl stearyl sulfate | | | | Mixture of cetyl stearyl alcohol, sodium lauryl sulfate and sodium cetyl stearyl sulfate | Kolliphor® CSL | 17, 18 |
| Mono- and di-glycerides | Mono- and di-glycerides | Glycerol monostearate 40-55 (type II) | | | Kolliwax® GMS II | 13, 18, 33 |
| Myristyl alcohol | Myristyl alcohol | | | | Kolliwax® MA | 18 |
| Octyldodecanol | Octyldodecanol | Octyldodecanol | | | Kollicream® OD | 15, 20, 21 |
| Oleyl alcohol | Oleyl alcohol | Oleyl alcohol | | | Kollicream® OA | 15, 20 |
| Partially-neutralized methacrylic acid and ethyl acrylate copolymer | Partially-neutralized methacrylic acid and ethyl acrylate copolymer | Methacrylic acid – ethyl acrylate copolymer (1:1), type B | | | Kollicoat® MAE 100 P | 11, 20, 26 |
| Poloxamer 124 | Poloxamer 124 | Poloxamer 124 | Polyoxyethylene (20) polyoxypropylene (20) glycol | | Kollisol® P 124 Geismar | 12, 17, 28, 30, 32, 33 |
| Poloxamer 188 | Poloxamer 188 | Poloxamer 188 | Polyoxyethylene (160) polyoxypropylene (30) glycol | | Kolliphor® P 188 Geismar, P 188 micro Geismar, P 188 Bio | 08, 09, 17, 18, 19, 20, 23, 25, 27, 28, 29, 33, 35 |
| Poloxamer 338 | Poloxamer 338 | Poloxamer 338 | | | Kolliphor® P 338 Geismar | 17, 18, 25, 27, 28, 29, 33 |
| Poloxamer 407 | Poloxamer 407 | Poloxamer 407 | Polyoxyethylene (196) polyoxypropylene (67) glycol | | Kolliphor® P 407 Geismar, P 407 micro Geismar | 08, 09, 17, 18, 25, 27, 28, 29, 31, 33 |
| Polyethylene glycol | Polyethylene glycol | Macrogol | Macrogol | | Kollisol® PEG 300, 300 G, 400, 400 G, 400 LA, 600, 600 LA, 1000, 1450, 3350, 8000 | 12, 16, 18, 19, 21, 25, 28, 30, 32 |
| Polyethylene glycol 15 hydroxystearate | Polyoxyl 15 hydroxystearate | Macrogol 15 hydroxystearate | | | Kolliphor® HS 15 | 16, 20, 23, 25, 27, 29, 31, 33, 36 |
| Polyoxyl 20 cetostearyl ether | Polyoxyl 20 cetostearyl ether | Macrogol cetostearyl ether 20 | | | Kolliphor® CS 20 | 16, 33 |
| Polyoxyl 35 castor oil | Polyoxyl 35 castor oil | Macrogolglycerol ricinoleate 35 | Polyoxyl 35 castor oil | | Kolliphor® EL, ELP | 16, 20, 23, 25, 27, 29, 33, 36 |
| Polyoxyl 40 hydrogenated castor oil | Polyoxyl 40 hydrogenated castor oil | Macrogolglycerol hydroxystearate | | | Kolliphor® RH 40 | 12, 16, 25, 27, 29, 33 |
| Polysorbate 20 | Polysorbate 20 | Polysorbate 20 | | | Kolliphor® PS 20 | 16, 21, 25, 27, 29, 33 |
| Polysorbate 60 | Polysorbate 60 | Polysorbate 60 | Polysorbate 60 | | Kolliphor® PS 60 | 16, 21, 25, 27, 29, 33 |
| Polysorbate 80 | Polysorbate 80 | Polysorbate 80 | | | Kolliphor® PS 80 | 12, 16, 21, 25, 27, 29, 33 |
| Polyvinyl acetate dispersion | Polyvinyl acetate dispersion | Polyvinyl acetate dispersion | | | Kollicoat® SR 30 D | 10, 12, 19 |
| Polyvinyl caprolactam – polyvinyl acetate – polyethylene glycol graft copolymer | | | | Polyvinyl caprolactam – polyvinyl acetate – polyethylene glycol graft copolymer | Soluplus® | 19, 20, 25, 26, 27, 32 |

Excipients

| Chemistry | USP-NF | Ph. Eur. | JP/JPE | Not monographed/ Co-processed excipients | BASF brand name | Page |
|--|-----------------------|----------------------------|-----------------------|--|---|--|
| Povidone | Povidone | Povidone | Povidone | | Kollidon® 12 PF, 17 PF, 25, 30, 30 LP, 90 F | 07, 13, 19, 20, 23, 25, 26, 27, 28, 31, 32 |
| Propylene glycol | Propylene glycol | Propylene glycol | Propylene glycol | | Kollisolv® PG | 12, 15, 16, 19, 20, 21, 28, 30, 32 |
| Pyrrolidone | | Pyrrolidone | | | Kollisolv® PYR | 15, 28, 30 |
| Sodium cetostearyl sulfate | | Sodium cetostearyl sulfate | | | Kolliphor® CSS | 17 |
| Sodium lauryl sulfate | Sodium lauryl sulfate | Sodium laurilsulfate | Sodium lauryl sulfate | | Kolliphor® SLS, SLS Fine | 08, 09, 17, 25, 27, 29 |
| SML 20 | | Sorbitan Laurate | | | Kolliphor® SML 20 | 12, 17 |
| Stearic acid 50 | Stearic acid 50 | Stearic acid 50 | Stearic acid 50 | | Kolliwax® S, S Fine | 09, 13, 18, 33 |
| Stearyl alcohol | Stearyl alcohol | Stearyl alcohol | Stearyl alcohol | | Kolliwax® SA | 09, 18, 21 |
| Triacetin | | | | | Kollisolv® GTA | 12, 16, 19, 20, 28, 30 |
| 90% Mannitol, 5% Crospovidone, 5% Polyvinyl acetate | | | | 90% Mannitol, 5% Crospovidone, 5% Polyvinyl acetate | Ludiflash® | 08 |
| 93% Lactose, 3.5% Povidone, 3.5% Crospovidone | | | | 93% Lactose, 3.5% Povidone, 3.5% Crospovidone | Ludipress® | 08 |
| 96.5% Lactose, 3.5% Povidone | | | | 96.5% Lactose, 3.5% Povidone | Ludipress® LCE | 08 |
| 80% Polyvinyl acetate and 19% Povidone, 0.8% Lauryl sulfate and 0.2% Silica (4:1) | | | | 80% Polyvinyl acetate and 19% Povidone, 0.8% Lauryl sulfate and 0.2% Silica (4:1) | Kollidon® SR | 08, 19, 20, 26 |
| 86.5% Lactose, 3.5% Ethylene glycol and vinyl alcohol graft copolymer, 9% Crospovidone, 1% Sodium stearyl fumarate | | | | 87% Lactose, 3% ethylene glycol and vinyl alcohol graft copolymer, 9% Crospovidone, 1% Sodium stearyl fumarate | Kollitab® DC 87L | 08 |

Liquid plasticizer. Also used as emulsifier and co-emulsifier in oral formulations.

Ph.Eur.: Sorbitan Laurate

APIs

| Chemistry | USP-NF | Ph. Eur. | JP/JPE | Not monographed/ Co-processed excipients | BASF brand name | Page |
|---|----------------------------|------------------------------|----------------------------|--|--|------|
| Azelaic acid | | | | Azelaic acid 99% (Dermaz [®] 99) | Azelaic acid 99% (Dermaz [®] 99) | 39 |
| Dexpanthenol | Dexpanthenol | Dexpanthenol | | | Dexpanthenol Ph. Eur. | 39 |
| Docosahexaenoic acid ethyl ester | | | | | Maxomega [®] DHA 95 EE AS | 40 |
| Eicosapentaenoic acid ethyl ester | | | Ethyl icosapentate | | Maxomega [®] EPA 96 EE Maxomega [®] EPA 97 EE | 40 |
| Ibuprofen | Ibuprofen | Ibuprofen | Ibuprofen | | Ibuprofen 25, 38, 50, 70 | 39 |
| Ibuprofen DC 85 W | Not monographed | | | | Ibuprofen DC 85 W | 39 |
| Ibuprofen sodium dihydrate | Ibuprofen sodium dihydrate | Ibuprofen sodium dihydrate | Ibuprofen sodium dihydrate | | Ibuprofen sodium dihydrate | 39 |
| Menthol | Menthol | Levomenthol | L-menthol | | L-menthol pharma | 39 |
| Omega-3-acid ethyl esters | Omega-3-acid ethyl esters | Omega-3-acid ethyl esters 90 | | | Omega-3-acid ethyl esters (K85EE) | 40 |
| Omega-3-acid triglycerides | | Omega-3-acid triglycerides | | | CN 600 TG | 40 |
| Polyvinylpyrrolidone iodine | Povidone-Iodine | Povidone, iodinated | Povidone-Iodine | | PVP-Iodine 30/06 | 39 |

Nutritional products

| Chemistry | USP-NF | Ph. Eur. | JP/JPE | Not monographed/ Co-processed excipients | BASF brand name | Page |
|----------------------------|--------|----------------------------|--------|---|-------------------------|------|
| Omega-3-acid triglycerides | | Omega-3-acid triglycerides | | | PronovaPure® 500:200 TG | 40 |
| Omega-3-acid triglycerides | | Omega-3-acid triglycerides | | | PronovaPure® 400:200 TG | 40 |
| Omega-3-acid triglycerides | | Omega-3-acid triglycerides | | | PronovaPure® 360:240 TG | 40 |
| Omega-3-acid triglycerides | | Omega-3-acid triglycerides | | | PronovaPure® 150:500 TG | 40 |
| Omega-3-acid ethyl esters | | Omega-3-acid ethyl esters | | | PronovaPure® 500:200 EE | 40 |
| Omega-3-acid ethyl esters | | Omega-3-acid ethyl esters | | | PronovaPure® 400:200 EE | 40 |
| Omega-3-acid ethyl esters | | Omega-3-acid ethyl esters | | | PronovaPure® 360:240 EE | 40 |
| Omega-3-acid ethyl esters | | Omega-3-acid ethyl esters | | | PronovaPure® 150:500 EE | 40 |
| Omega-3-acid ethyl esters | | Omega-3-acid ethyl esters | | | PronovaPure® 460:180 EE | 40 |
| Omega-3-acid ethyl esters | | Omega-3-acid ethyl esters | | | PronovaPure® 46:38 EE | 40 |

Exceptional quality & regulatory support



The Pharma Solutions Regulatory Team has global and regional presence with a decades-long track record of enabling our Pharma customers to register finished drug products worldwide. We do this by efficiently offering high-quality expert solutions through proactive and transparent communication.

Our global Quality Team supports our customers worldwide with regards to any quality-related questions.

A regional footprint secures quick and regional-specific solutions in alignment with global standards for topics like audits, statements and complaints.

In close exchange with authorities and international associations, we are constantly improving our quality systems to provide the best service to our customers in more and more demanding markets. For this purpose we cooperate closely with the production sites and ensure GMP-compliant production and testing in accordance with the latest requirements of the pharmaceutical authorities.



Access to standard quality and regulatory documentation is now more efficient than ever. Retrieve your documents 24/7 or sign-up for new RegXcellence®, your free online Quality & Regulatory Assistant that provides a unified platform for compliance documents, filing assistance and audit information.

Sign-up today at: <https://info-mypharma.basf.com>

Contact us for pricing. pharma-solutions@basf.com

 BASF Pharma Solutions
pharma.basf.com

This document, or any information provided herein does not constitute a legally binding obligation of BASF and has been prepared in good faith and is believed to be accurate as of the date of issuance. Unless expressly agreed otherwise in writing in a supply contract or other written agreement between you and BASF:

- (a) To the fullest extent not prohibited by the applicable laws, BASF EXPRESSLY DISCLAIMS ALL OTHER REPRESENTATIONS, WARRANTIES, CONDITIONS OR GUARANTEES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, WRITTEN OR ORAL, BY FACT OR LAW, INCLUDING ANY IMPLIED WARRANTIES, REPRESENTATIONS OR CONDITIONS OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, SATISFACTORY QUALITY, NON-INFRINGEMENT, AND ANY REPRESENTATIONS, WARRANTIES, CONDITIONS OR GUARANTEES, ARISING FROM STATUTE, COURSE OF DEALING OR USAGE OF TRADE and BASF HEREBY EXPRESSLY EXCLUDES AND DISCLAIMS ANY LIABILITY RESULTING FROM OR IN CONNECTION WITH THIS DOCUMENT OR ANY INFORMATION PROVIDED HEREIN, including, without limitation, any liability for any direct, consequential, special, or punitive damages relating to or arising therefrom, except in cases of (i) death or personal injury to the extent caused by BASF's sole negligence, (ii) BASF's willful misconduct, fraud or fraudulent misrepresentation or (iii) any matter in respect of which it would be unlawful for BASF to exclude or restrict liability under the applicable laws;
- (b) Any information provided herein can be changed at BASF's sole discretion anytime and neither this document nor the information provided herein may be relied upon to satisfy from any and all obligations you may have to undertake your own inspections and evaluations;
- (c) BASF rejects any obligation to, and will not, automatically update this document and any information provided herein, unless required by applicable law; and
- (d) The user is responsible for confirming that the user has retrieved the most current version of this document from BASF as appropriate

© Trademark of BASF registered in various countries

© 2025 BASF